

SPECIAL REPORT

EBMT activity survey 2004 and changes in disease indication over the past 15 years

A Gratwohl¹, H Baldomero¹, K Frauendorfer² and A Urbano-Ispizua³, for the Joint Accreditation Committee of the International Society for Cellular Therapy ISCT and the European Group for Blood and Marrow Transplantation EBMT (JACIE)

¹Division of Hematology, Department of Internal Medicine, University Hospital Basel, Basel, Switzerland; ²Institute for Operations Research and Computational Finance, University of St Gallen, St Gallen, Switzerland and ³JACIE office, Hospital Clinic, Barcelona, Spain

This fifteenth annual European Group for Blood and Marrow Transplantation activity report lists the transplant activity in Europe in 2004 and documents the changes in indication over the past 15 years. In 2004, there were 22 216 first hematopoietic stem cells (HSCT), 7407 allogeneic (33%), 14 809 autologous (67%) and 4378 additional re- or multiple transplants reported from 592 centres in 38 European and five affiliated countries. Main indications were leukemias (7045 (32%; 78% allogeneic)); lymphomas (12 310 (55%; 94% autologous)); solid tumors (1759 (8%; 93% autologous)) and nonmalignant disorders (1015 (5%; 92% allogeneic)). In comparison, 145 teams from 20 countries performed 4234 HSCT (2137 allogeneic, 50%; 2097 autologous, 50%) in 1990. The overall increase was accompanied by major changes. Stem cell source changed from bone marrow to peripheral blood. More than one-third of allogeneic HSCT are now from unrelated donors. Reduced intensity conditioning is employed for one-third of allogeneic HSCT. Leukemias for allogeneic and lymphoproliferative disorders for autologous HSCT continue to increase. The decline in HSCT for chronic myeloid leukemia appears to level off for the first time since 1999. These data are informative for patient counselling and decision making for health care professionals.

Bone Marrow Transplantation (2006) 37, 1069–1085.
doi:10.1038/sj.bmt.1705377

Keywords: hematopoietic stem cell transplantation; Europe; transplant rates; leukemia; solid tumor; non-malignant diseases

patients with severe malignant or hematopoietic stem cells malignant, acquired or congenital disorders of the hematopoietic system or with chemo-radiosensitive tumors.^{1–3} HSC has seen rapid expansion over the last decade and the increasing demand for this high-cost procedure can present a challenge for health care systems in any country. Precise information on current use and trends is essential for patients, physicians and health care providers alike.^{4,5}

The activity survey of the European Group for Blood and Marrow Transplantation (EBMT) was designed in 1990 to provide this information in a most efficient way and to disseminate it rapidly on an annual basis.⁶ All EBMT members and affiliated teams, known to perform transplants, were requested to report their numbers of patients transplanted by indication, stem cell source and donor type on an annual basis. The initial survey sheet was slightly changed over the years, to respond to changes in indication and to collect additional generic information on the numbers of re- or multiple transplants, on the percentage of cord blood HSCT and on the percentage of transplants with reduced intensity conditioning (RIC HSCT). The EBMT survey was adopted by the General Assembly as a mandatory self-reporting system. It forms now an integral part of a comprehensive quality assurance program JACIE (Joint Accreditation Committee of the International Society for Cellular Therapy (ISCT) and the EBMT (<http://www.EBMT.org>/<http://www.JACIE.org>)). With a follow-up of 15 years since its introduction clear information becomes visible. Major changes have occurred concerning donor type, stem cell source, indications and technology. This is reflected in this 15th survey, which includes presentation of the 2004 data.

Introduction

Transplantation of hematopoietic stem cells (HSCT) offers a unique opportunity for long-term disease control to many

Patients and methods

Data collection and validation

All participating teams reported their data for 2004 by indication, stem cell source and donor type as listed in Table 1. Data were validated by the reporting team, which received a computer printout of entered data, and by crosschecking with national registries. Onsite visits of selected teams were part of the quality control program.

Correspondence: Dr A Gratwohl, Division of Hematology, Department of Internal Medicine, University Hospital Basel, Petersgraben 4, Basel CH – 4031, Switzerland.

E-mail: hematology@uhbs.ch

Received 7 March 2006; accepted 20 March 2006

Table 1 Number of patients treated in Europe during the year 2004 with a first hematopoietic stem cell transplant listed by indication, donor type and stem cell source

Survey 2004 Teams = 592	Donor source No. of patients												
	Allogeneic						Autologous		Total				
	Family			Unrelated			BM	BM+	Allo	Auto	Total		
	HLA-id		Non-id	Twin		BM	PBPC	Only	PBPC				
	BM	PBPC	BM	PBPC	BM	PBPC							
<i>Leukemias</i>	877	2103	25	241	6	18	692	1562	138	1383	5524	1521	7045
Acute myeloid leukemia	343	1021	11	133	2	9	211	674	110	919	2404	1029	3433
First complete remission	265	672	4	34	2	7	87	283	86	788	1354	874	2228
Not first complete remission	78	349	7	99		2	124	391	24	131	1050	155	1205
Acute lymphatic leukemia	297	365	8	68	2	2	242	396	25	205	1380	230	1610
First complete remission	185	201	6	21	2		115	177	15	139	707	154	861
Not first complete remission	112	164	2	47		2	127	219	10	66	673	76	749
Chronic myeloid leukemia	137	323	1	18	1	2	113	207	0	30	802	30	832
Chronic phase	110	228		8	1	1	75	101		11	524	11	535
Not first chronic phase	27	95	1	10		1	38	106		19	278	19	297
MDS incl. Sec AL	66	221	2	14	1	3	91	151		26	549	26	575
MPS	26	65	3	6		1	27	71		11	199	11	210
Chronic lymphatic leukemia	8	108		2		1	8	63	3	192	190	195	385
<i>Lymphoproliferative disorders</i>	76	413	2	33	0	13	42	189	123	11419	768	11542	12310
Plasma cell disorders – MM	13	101		4			6	32	5	5319	164	5324	5488
Plasma cell disorders – other		6					1	4	2	212	11	214	225
Hodgkin's lymphoma	8	52		11			5	28	43	1503	104	1546	1650
Non-Hodgkin lymphoma	55	254	2	18		5	30	125	73	4385	489	4458	4947
<i>Solid tumors</i>	7	89	0	9	0	0	1	17	56	1580	123	1636	1759
Neuroblastoma	3			1					26	343	4	369	373
Soft tissue sarcoma		2							5	117	2	122	124
Germinal tumors									7	300	0	307	307
Breast cancer		9		1						190	10	190	200
Ewing		2		4					2	235	6	237	243
Renal cancer	1	50		2				8	1	30	61	31	92
Melanoma		1								1	1	1	2
Colon cancer		11						5		10	16	10	26
Other solid tumors	3	14		1			1	4	15	354	23	369	392
<i>Non-malignant disorders</i>	332	181	48	69	0	2	172	134	2	75	938	77	1015
Bone marrow failure – SAA	135	79	2	10		2	59	47			334	0	334
Bone marrow failure – other	26	21	4	4			17	10		1	82	1	83
Hemoglobinopathies – thal	63	55	6	5			24	7			160	0	160
Hemoglobinopathies – other	18	7	1	2			3	4			35	0	35
Immune deficiencies	69	13	30	41			46	48		4	247	4	251
Inherited disorders of Metabolism	18	4	5	7			21	17			72	0	72
Auto immune disease	3	2					2	1	2	70	8	72	80
Others	11	8	1	4	1		12	17	2	31	54	33	87
Total	1303	2794	76	356	7	33	919	1919	321	14488	7407	14809	22216

Teams

For the 2004 report, 612 teams in 43 participating countries were contacted of which 592 reported their numbers. This corresponds to a 97% return rate of active teams and includes 481 of the 494 active EBMT member teams reporting to the survey. Twenty teams known by the investigators to have been performing HSCT in 2004 were also contacted, but chose not to reply or, for unknown reasons, failed to reply in spite of several efforts to reach them. No major transplant team in Europe is missing from this list. Contacted teams are listed in the Appendix A in alphabetical order according to country, city and EBMT centre code. We received information that in 2004 no blood

or marrow transplants were performed in the following European countries: Albania, Andorra, Armenia, Georgia, Liechtenstein, Malta, Moldavia, Monaco, San Marino and The Vatican.

By EBMT tradition, some non-European countries; Algeria, Iran, Israel, Saudi Arabia and Tunisia are included in the survey and the analyses.

Definitions

The survey lists patients and transplants separately. For the determination of transplant rates, only first transplants were considered. Information on additional transplants,

hence on second, third or fourth HSCT in a patient with a previous HSCT was collected only generically for each team and defined as follows: re-transplants (autologous or allogeneic) were defined as any HSCT for rejection or relapse; multiple transplants were defined when they were part of a planned double or triple transplant protocol. Information on stem cell source was collected as bone marrow or peripheral blood. Combined bone marrow and peripheral blood transplants or cord blood transplants were listed as peripheral blood HSCT. Information on cord blood transplants was collected only as a generic number per year for each individual team. Similarly, information on reduced intensity conditioning was collected only as a total for each team, not for individual transplants. Definitions for RIC HSCT were defined as recently published.⁷

Transplant rates

Transplant rates were defined as the number of HSCT per 10 million inhabitants.⁵ They were computed by disease indication and donor type for each country, as previously defined. Transplant rates were assessed for all HSCT and separately for autologous, allogeneic and unrelated HSCT. They were also assessed for RIC allogeneic HSCT donor lymphocyte infusions (DLI) and cord blood HSCT. They were computed for all individual disease categories as given in Table 1. Transplant rates refer to the number of transplants in a given country compared to its own population. The survey cannot make adjustments for patients who cross borders and receive their HSCT in a foreign country.

Population data were obtained from the US census office (<http://www.census.gov>).

Results

Participating teams

Of the 592 teams reporting HSCT in 2004, 342 (58%) did both allogeneic and autologous transplants; 224 (38%) restricted their activity to autologous, six teams (1%) to allogeneic transplants only. Twenty teams (3%) reported having performed no transplants in 2004.

Numbers of HSCT in 2004

First transplants 2004. A total 22 216 first transplants, 7407 (33%) allogeneic and 14 809 (67%) autologous were carried out in 2004 (Table 1). This represents an increase of 1188 transplants or an increase of 5% compared to 2003, when there were 21 028 first transplants (7091 allogeneic, 13 937 autologous). Numbers of allogeneic HSCT increased by 4% from 7091 in 2003 to 7407 in 2004; numbers of autologous HSCT by 6% from 13 937 in 2003 to 14 809 in 2004.

The development in numbers of transplant teams and transplants since 1973 when EBMT was founded is illustrated in Figure 1. In 1990, at the introduction of the survey, 143 teams performed 4234 HSCT (2137 allogeneic (50%) and 2097 autologous (50%) HSCT).

Additional transplants 2004. There were 1838 additional re-transplants (1048 allogeneic/790 autologous) and 2540

additional planned multiple transplants (501 allogeneic/2039 autologous). Thus, there were a total 26 594 HSCT procedures, 8956 allogeneic (34%) and 17 638 autologous (66%) performed in 2004. This corresponds to an increase in 224 re-transplants (150 allogeneic/74 autologous) or of 12% in re-transplants as compared to 2003. The numbers of planned multiple transplants behaved differently. There was an overall decrease of 1% in planned multiple transplants as compared to 2003. In allogeneic transplants there was a increase from 396 in 2003 to 501 (+21%) in 2004 but with autologous transplants there was a decrease from 2169 in 2003 to 2039 (-6%) in 2004. Owing to the design of the survey, no disease specific information can be given on the indications for the additional transplants.

Indications and donor type

Main indications were *lymphoproliferative disorders* with 12 310 patients (55%), 768 patients with allogeneic HSCT (6%), 11 542 with autologous HSCT (94%); *leukemias* with 7045 patients (32%), 5524 patients with allogeneic (78%), 1521 with autologous (22%) HSCT; *solid tumors* with 1759 patients (8%), 123 with allogeneic HSCT (7%), 1636 with autologous HSCT (93%) and *nonmalignant disorders* with 1015 patients (5%), 938 with allogeneic HSCT (92%), 77 with autologous HSCT (8%). The latter, autologous HSCT for nonmalignant disorders predominantly include patients with autoimmune disorders. An additional 87 patients, 54 with allogeneic HSCT and 33 with autologous HSCT were listed as 'other indications'.

For the 7407 allogeneic first transplants, HLA-identical siblings were used as donors for 4097 (55%) of the recipients, other family members for 432 (6%) of the recipients, a syngeneic twin for 40 (1%) of the recipients and an unrelated volunteer donor for 2838 (38%) of the recipients. Alternative donors were primarily used for patients with leukemias or nonmalignant disorders.

Stem cell source

Of the 14 809 autologous first transplants, 321 (2%) were bone marrow derived, 14 488 (98%) from peripheral blood




Figure 1 Evolution of hematopoietic stem cells (HSCT) in Europe from 1973 to 2004. Lines represent numbers of participating teams (green), first transplants for autologous (red) and allogeneic (blue) HSCT. Numbers from 1990 to 2004 are derived from the European Group for Blood and Marrow Transplantation (EBMT) activity survey. Numbers for 1973 and 1983 were collected retrospectively in 1993 (ref).

stem cells or from combined bone marrow and peripheral blood stem cell transplants (Table 1). Of the 7407 allogeneic first transplants, 31% were bone marrow and 69% were peripheral blood stem cell transplants. The proportion of peripheral blood as stem cell source varied depending on donor type. It was 68% for HLA-identical sibling donor transplants and 68% for unrelated donors. 82% for HSCT from other family members, 83% for twin donors.

A total 281 allogeneic HSCT were cord blood transplants in 2004. This corresponds to 3% of all allogeneic transplants.

Transplant rates

Transplant rates in 2004. There were marked differences in transplant rates between European countries and countries affiliated with EBMT as presented in Figure 2. There was the previously reported difference between Eastern and Western European countries; these differences related to all transplants (Figure 2a), to allogeneic HSCT (Figure 2b) and to autologous HSCT (Figure 2c). Of interest to note is that countries with similar total transplant rates and higher transplant rates for allogeneic HSCT had lower transplant rates for autologous HSCT and vice versa.

Changes over time from 1990 to 2004

Stem cell source. Stem cell source was almost completely bone marrow in 1990,⁶ it changed rapidly to peripheral blood for autologous HSCT, and more slowly and later for allogeneic HSCT (Figure 3). It is of interest to note that the proportion of peripheral blood as stem cell source was similar for the first time in 2004 in allogeneic HSCT from HLA-identical siblings and from unrelated donors.

Conditioning. Information on RIC HSCT is collected only since 1999. There were very few RIC HSCT before 1998 according to the EBMT megafile and a huge increase from 1999 to 2001 (Figure 4). In 2004, there were a total 2747 RIC HSCT. This corresponds to 31% of all allogeneic HSCT; a similar proportion over the past 3 years. There were marked differences in use of RIC HSCT amongst European countries with ranges from <1% (in 13 countries) to as much as 71% (in Austria) (Figure 2d).

Changes in indication. Numbers of allogeneic (Figure 5a) and autologous (Figure 5b) HSCT for the main disease indications over time are illustrated in Figure 5. There were most marked increases at a rate of about 200 HSCT per year for leukemias in allogeneic and about 800 HSCT per year for lymphoproliferative disorders in autologous HSCT




Figure 2 Transplant rates (number of hematopoietic stem cells (HSCT) per 10 million inhabitants) in European countries in 2004 (a) All HSCT combined. (b) Allogeneic HSCT only. (c) Autologous HSCT only. (d) Proportion of reduced intensity conditioning (RIC) HSCT in percent of allogeneic HSCT.




Figure 3 Change in stem cell source in Europe from 1990 to 2004. Curves reflect the proportion of peripheral blood in percent as stem cell source for autologous (blue) or allogeneic (red) hematopoietic stem cells (HSCT).




Figure 4 Evolution of RIC hematopoietic stem cells (HSCT) in Europe from 1990 to 2004. Curves reflect absolute numbers of allogeneic HSCT and absolute numbers of RIC allogeneic HSCT.

and steady increases of about 50 HSCT per year for nonmalignant diseases in allogeneic and 50 HSCT per year for leukemias in autologous HSCT.

There were major differences, when the individual disease categories are analysed as illustrated in Figure 6. For *acute myeloid leukemia* (Figure 6a) there was a steady increase in allogeneic HSCT, even more so for AML first CR in the past 3 years. Autologous HSCT in first CR did increase up to the year 2000, since then they plateaued. Autologous HSCT beyond first CR showed a slow decline. For *acute lymphoblastic leukemia* (Figure 6b) there was an increase in allogeneic HSCT and a marked decline in autologous HSCT. Of interest to note, numbers of allogeneic HSCT in 1.CR increased at a higher rate than HSCT for ALL beyond first CR and were for the first time higher than HSCT beyond 1.CR. For *chronic myeloid leukemia* (Figure 6c) there was a massive increase in HSCT up to the year 1999 (then the most frequent indication for an allogeneic HSCT) with a rapid decline.⁴ This decline stopped in 2004 with similar numbers in 2003 (791)⁸ and 2004 (802). A high increase in allogeneic HSCT is observed




Figure 5 Evolution of transplant numbers for the main disease categories in Europe from 1990 to 2004. (a) Allogeneic hematopoietic stem cells (HSCT). (b) Autologous HSCT.

for allogeneic HSCT for *myelodysplastic-myeloproliferative disorders* (Figure 6d) with stable low numbers for autologous HSCT. A different pattern is observed for *chronic lymphocytic leukemia* with steadily increasing numbers for allogeneic, stable numbers since 1999 for autologous HSCT (Figure 6e). Plasma cell disorders (Figure 6f) shows a rapid continuing increase in autologous HSCT. Numbers for allogeneic HSCT might be misleading in this specific disease. Only first transplants are captured by the survey. In myeloma, many teams use a tandem-autologous allogeneic HSCT approach. This is not captured by the survey. In *lymphoma*, the main increase is seen in autologous HSCT for non-Hodgkins lymphoma (Figure 6g). Transplants for solid tumors show changing patterns with increases for *neuroblastoma* and stable low numbers for glioma in autologous HSCT (Figure 6h), increases in autologous HSCT for Ewings sarcoma (Figure 6i) and decreasing numbers for soft tissue tumors. Most marked is the previously well-described increase and decrease in autologous HSCT for breast cancer (Figure 6j). Numbers of allogeneic HSCT for solid tumors remained low throughout the whole observation period (Table 1). Allogeneic HSCT did increase for the *bone marrow failure syndromes, congenital disorders* and for *hemoglobinopathies* (Figure 6k).




Figure 6 Evolution of transplant numbers for specified disease categories in Europe from 1990 to 2004. (a) Acute myeloid leukemia. (b) Acute lymphoblastic leukemia. (c) Chronic myeloid leukemia. (d) Myelodysplastic and myeloproliferative syndromes. (e) Chronic lymphocytic leukemia. (f) Plasma cell disorders. (g) Hodgkin's and non-Hodgkin's lymphoma. (h) Glioma and Neuroblastoma; autologous HSCT only. (i) Ewing's sarcoma and soft tissue sarcoma; autologous hematopoietic stem cells (HSCT) only. (j) Breast cancer; autologous HSCT only. (k) Nonmalignant disorders; allogeneic HSCT only.




Figure 6 Continued.

Discussion

The present data document that HSCT is a well-established procedure in Europe in 2004. Autologous and allogeneic stem cells from different sources were used for a broad variety of disorders. Peripheral blood was the main source of stem cells with the few exceptions of allogeneic HSCT for nonmalignant disorders. Autologous HSCT was the preferred choice for those disease categories, where primary focus lies on support for dose intensification of chemoradiotherapy, that is in specified solid tumors and lymphomas. Allogeneic HSCT was the preferred choice where focus was on replacing a defective hemopoiesis as in congenital disorders or bone marrow failure syndromes or in malignant diseases involving hemopoiesis and in which a graft-versus-tumor effect is most desired, for example, leukemias.^{9,10} As such, data reflect current status.

More informative are data, if they are put in context over time. It is illustrative to note the differences in trends amongst the leukemias with a most marked increase in allogeneic HSCT for early acute leukemias, myelodysplastic and myeloproliferative syndromes and chronic lymphocytic leukemia. In chronic myeloid leukemia, the imatinib-induced fall in HSCT has stabilised and numbers remained similar between 2003 and 2004, with still higher numbers for HSCT in first chronic phase compared to later stages of the disease.^{5,11,12} According to the structure of the survey, no information is yet available on the proportion of these

patients with imatinib pre-treatment or imatinib failure. Numbers of autologous HSCT increased mainly for lymphoproliferative disorders. This is clearly explained by the several prospective randomised studies which showed an advantage of autologous HSCT compared to conventional therapy.¹³⁻¹⁵ There are a few specific comments. Increase in AML in first CR is most marked during the past years. This is most likely the consequence of increased use of RIC HSCT in elderly patients. It cannot be proven by the survey. Unexplained remains the higher increase of allogeneic HSCT for ALL in first CR compared to later stages. Unexplained remains the pattern of transplant evolution in CLL. In addition, numbers of allogeneic HSCT, specifically for multiple myeloma or Hodgkin's disease might be misleading. Owing to the nature of the survey, the information on allogeneic HSCT after a preceding autologous HSCT cannot be captured.¹⁶⁻¹⁸ The fact, that numbers of double transplants have declined for autologous but increased for allogeneic HSCT support the assumption, that allogeneic HSCT have increased for myeloma and lymphoma. The survey for 2005 will be adapted and will yield such information.

The survey gives very limited information on technological aspects of HSCT procedure. Still, it documents the change in stem cell source where now peripheral blood is the preferred source of choice for all situations, with the exception of bone marrow failure syndromes.^{8,19,20} It is interesting that the proportion reaches similar values for

unrelated donors and HLA-identical siblings. Mobilised stem cell harvesting is now an accepted modality in all European countries. The fact, that most twins donate peripheral blood illustrates that peripheral blood is the preferred choice amongst donors.²¹

The survey gives some generic information on the use of RIC HSCT.^{9,10} About one-third of all allogeneic HSCT are RIC HSCT, the trend appears now stable with a similar proportion over the past 3 years. Still and important to note, there was a marked discrepancy in use between the different European countries. This difference reflects the divergent opinions amongst the transplant physicians about the value of this approach in general. It reflects probably best the need for prospective trials which should evaluate the role of RIC HSCT compared to standard conditioning or compared to alternative treatment.

As usual, the survey gives no information on outcome. These data will be reported later, when this information becomes available with sufficient follow-up. As it stands, the survey presents current status and trends. It forms the basis for decision making for individual patients, physicians, transplant teams and health care providers.

Acknowledgements

The cooperation of all participating teams and their staff (listed in the Appendix), the EBMT secretariat (F McDonald, E McGrath, S Notely), the European EBMT Data Office in Paris (V Chesnel, NC Gorin), the EBMT Registry Subcommittee (P Ljungman, C Ruiz de Elvira), the French Registry SFGM (JP Jouet, Z Chir), the Dutch Registry TYPHON (A Hagenbeek, A v Biezen, M. Sneets), the Austrian Registry (H Greinix, B Lindner), the Italian Registry (M Vignetti, A Bacigalupo, R Oneto, B Bruno), the German Registry (H Ottinger, M Westphal), the Swiss Registry (U Schanz, H Baldomero), the British Registry (K Towlson, J Apperley, M Wilson), the Turkish Registry (G Gurman, M Arat, F Arpacı, M Ertem), the Czech Registry (K Benesova, M Trnkova), and the Spanish Transplantation Office (ONT) (B Miranda) is greatly appreciated. The authors also thank S Stöckli for excellent secretarial assistance, as well as L John for technical assistance with data management.

The work was supported in part by the European Leukemia Net LSH-2002-2.2.0-3, by a grant from the Swiss National Research Foundation, 3200BO-106105/1, the Swiss Cancer League, the Regional Cancer League and the Horton Foundation. EBMT is supported by grants from the corporate members: Amgen Europe, Hoffmann-La Roche Ltd., Gilead Sciences, Baxter Oncology, Pharmacia Corporation, Chugai-Aventis, Fresenius HemoCare, SangStat, Schering AG, Gambro BCT, Elan Pharmaceuticals, Miltenyi Biotec GmbH, Therakos, Wyeth-Lederlé, Astra, Cobe International, Nextar, Liposome Co, Imtix, Octapharma, Stem Cell Technologies, ICN Pharmaceuticals and Bristol-Meyers Squibb.

References

- 1 Thomas ED. Bone marrow transplantation: a review. *Semin Hematol* 1999; **36** (Suppl 7): 95–103.
- 2 Horowitz MM. Uses and growth of hematopoietic cell transplantation. In: Forman SJ, Blume KG, Thomas ED (eds). *Hematopoietic Cell Transplantation*, 3rd edn. Blackwell Scientific Publishers Inc.: London, New York, 2003, pp 9–15.

- 3 Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE et al. Bone-marrow transplantation (second of two parts). *N Engl J Med* 1975; **292**: 895–902.
- 4 Gratwohl A, Baldomero H, Horisberger B, Schmid C, Passweg J, Urbano-Ispizua A, Accreditation Committee of the European Group for Blood and Marrow Transplantation (EBMT). Current trends in hematopoietic stem cell transplantation in Europe. *Blood* 2002; **100**: 2374–2386.
- 5 Gratwohl A, Passweg J, Baldomero H, Horisberger H, Urbano-Ispizua A, for the Accreditation Committee of the European Group for Blood and Marrow Transplantation (EBMT). Economics, health care systems and utilisation of haematopoietic stem cell transplants in Europe. *Br J Haematol* 2002; **117**: 451–468.
- 6 Gratwohl A. Bone marrow transplantation activity in Europe 1990. Report from the European Group for Bone Marrow Transplantation (EBMT). *Bone Marrow Transplant* 1991; **8**: 197–201.
- 7 Ljungman P, Urbano-Ispizua A, Cavazzana-Calvo M, Demirer T, Dini G, Einsele H et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. *Bone Marrow Transplant* 2006; **37**: 439–449.
- 8 Gratwohl A, Baldomero H, Schmid O, Horisberger B, Bargetzi M, Urgano-Ispizua A. Change in stem cell source for hematopoietic stem cell transplantation (HSCT) in Europe: a report of the EBMT activity survey 2003. *Bone Marrow Transplant* 2005; **36**: 575–590.
- 9 Barrett J, Childs R. Non-myeloablative stem cell transplants. *Br J Haematol* 2000; **111**: 6–17.
- 10 Slavin S. Smarter rather than stronger treatment of haematological malignancies and non-malignant indications for stem-cell transplantation. *Lancet* 2004; **364**: 122–124.
- 11 Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. *N Engl J Med* 2001; **344**: 1031–1037.
- 12 O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al., IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic phase chronic myeloid leukemia. *N Engl J Med* 2003; **348**: 994–1004.
- 13 Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. *N Engl J Med* 1995; **333**: 1540–1545.
- 14 Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C, et al., Groupe Ouest-Est des Leucemies et des Autres Maladies du Sang. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. *N Engl J Med* 2004; **25**: 1287–1295.
- 15 Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myelome. *N Engl J Med* 1996; **335**: 91–97.
- 16 Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, et al., Inter Groupe Francophone du Myelome. Single versus double autologous stem-cell transplantation for multiple myeloma. *N Engl J Med* 2003; **349**: 2495–2502.
- 17 Gibson J, Ho PJ, Joshua D. Evolving transplant options for multiple myeloma: autologous and nonmyeloablative allogeneic. *Transplant Proc* 2004; **36**: 2501–2503.
- 18 Gutman JA, Bearman SI, Nieto Y, Sweetenham JW, Jones RB, Shpall EJ et al. Autologous transplantation followed closely by reduced-intensity allogeneic transplantation as

- consolidative immunotherapy in advanced lymphoma patients: a feasibility study. *Bone Marrow Transplant* 2005; **36**: 443–451.
- 19 Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R *et al*. Transplantation of bone marrow as compared with peripheral blood cells from HLA-identical relatives in patients with hematologic cancers. *N Engl J Med* 2001; **344**: 175–181.
- 20 Schmitz N, Beksac M, Hasenclever D, Bacigalupo A, Ruutu T, Nagler A *et al*. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard risk leukemia. *Blood* 2002; **100**: 761–767.
- 21 Favre G, Beksac M, Bacigalupo A, Ruutu T, Nagler A, Gluckman E, *et al*. European Group for Blood and Marrow Transplantation (EBMT). Differences between graft product and donor side effects following bone marrow or stem cell donation. *Bone Marrow Transplant* 2003; **32**: 873–880.

Appendix A 2004

List of transplant centres in 2004 (number of first transplants (total transplants) allogeneic/autologous)

Albania: no report
Andorra: no report
Armenia: no report

Algeria (1 team: 140 (141) 106/34)
Alger, Centre Pierre et Marie Curie, CIC 703, R Hamladji (140 (141) 106/34)

Austria (15 teams: 289(382) 112/177)
Graz, Karl Franz University Hospital (onco), CIC 278, H Samonigg (2 (2) 0/2)
Graz, Karl Franz University Hospital (hem), CIC 308, W Linkesch (46 (69) 14/32)
Graz, Universitäts-Kinderklinik (hem, onco), CIC 593, Ch Urban (19 (24) 7/12)
Innsbruck, Universitätsspital (hem, onco), CIC 271, G Gastl, D Nachbaur (42 (52) 23/19)
Innsbruck, Universitätsspital, Internal Medicine (onco), CIC 516, E Woell (0 (0) 0/0)
Klagenfurt, General Hospital Klagenfurt, D Geissler, M Heistingner (7 (7) 0/7)
Linz, AO Krankenhaus (onco), I Medizin, MA Fridrik (3 (4) 0/3)
Linz, AOK der Elisabethinen, Internal Medicine, CIC 594, D Lutz, O Krieger (36 (54) 8/28)
Salzburg, LKA Salzburg (onco), CIC 356, R Greil (7 (11) 0/7)
Vienna, AKH, Universitätsklinik für Innere Medizin I (onco), CIC 227, HT Greinix, P Kalhs (65 (72) 38/27)
Vienna-Lainz, Krankenhaus der Stadt Wien-Lainz, 5. Med Onko, K Geissler, E Ulsperger (0 (0) 0/0)
Vienna, St Anna Kinderspital (hem, onco), CIC 528, H Gadner, C Peters (29 (40), 22/7)
Vienna, Hanusch-Krankenhaus (hem, onco), CIC 743, E Koller (14 (20) 0/14)
Vienna, Donauspital, CIC 767, W Hinterberger (4 (6) 0/4)
Vienna, Wilhelminenspital (hem, onco), CIC 828, H Ludwig (15 (21) 0/15)

Azerbaijan (1 team: 0 (0) 0/0)
Baku, Azerbaijan Central Clinic Hospital, CIC 186, S Dincer (0 (0) 0/0)

Belarus, Republic of (2 teams: 34 (34) 8/26)
Minsk, Belorussian Center (hem, onco, peds), CIC 591, O Aleinikova (34 (34) 8/26)
Minsk, Hospital no. 9, N Milanovitch (no report)

Belgium (20 teams: 546 (672) 189/357)
Antwerpen, Stuivenberg ZH, CIC 339:1, P Zachée (47 (64) 13/34)
Antwerpen-Edegem, University Antwerpen (hem), CIC 339:2, W Schroyens (27 (30) 9/18)
Antwerpen, A.Z. Middelheim (hem), CIC 783, R de Bock (5 (6) 0/5)
Brugge, A.Z. St Jan (hem), CIC 506, D Selleslag, A Van Hoof, J Van Droogenbroeck, K Van Eygen (57 (69) 15/42)

Brussels, Institut Jules Bordet and the Children's University Hospital, CIC 215, D Bron, E Sariban, C Devalck, A Ferster (34 (53) 17/17)
Brussels, Clinique universitaire St Luc (hem, ads), CIC 234, A Ferrant (43 (53) 20/23)
Brussels, Clinique Universitaire St Luc (peds), CIC 234, C Vermeylen (11 (11) 5/6)
Brussels, Cliniques Universitaires St Luc, (onco), JP Machiels (0 (0) 0/0)
Brussels, Hôpital Erasme (hem), CIC 596, W Feremans, A Kentos, M Lambermont, A Deweiwere (14 (14) 0/14)
Brussels, University Hospital (hem, onco), CIC 630, B Van Camp, A Schots (26 (32) 7/19)
Charleroi, Hopital Notre-Dame (hem, onco), CIC 349, M André (11 (11) 3/8)
Charleroi, University Hospital (hem), CIC 804, A Triffet (1 (1) 0/1)
Gent, University Hospital (hem, ads, peds), CIC 744, LA Noens (37 (39) 19/18)
Haine St Paul, Hôpital de Jolimont (hem), CIC 234, A Delannoy, C Ravoot, N Straetmans (9 (12) 1/8)
Hasselt, Virgajesse Ziekenhuis (hem), CIC 632, D Vanstraelen, G Bries, V Madoe (30 (32) 0/30)
Leuven, University Hospital Gasthuisberg (hem, ads, peds), CIC 209, MA Boogaerts, P Vandenberghe, J Maertens (84 (96) 36/48)
Liège, CHR La Citadelle (hem, onco), CIC 353, B De Prijck (13 (15) 0/13)
Liège, University Hospital Sart-Tilman (hem), CIC 726, Y Béguin (53 (76) 32/21)
Roeselare, H Hartziekenhuis (hem, onco), CIC 646, F Van Aelst, J Tytgat, J Demol (22 (27) 5/17)
Yvoir, Clinique universitaire de Mont-Godinne (hem), CIC 234, C Doyen (22 (31) 7/15)

Bosnia-Herzegovina (1 team: 4 (4) 3/1)
Tuzla, University Clinical Centre of Tuzla (hem), CIC 647, M Malesevic (4 (4) 3/1)

Bulgaria (1 team: 15 (15) 3/12)
Sofia, Pediatric Hospital for Oncohematology and Bone Marrow Transplantation (peds hem-onco), CIC 346, D Bobev, B Avramova, M Yordanova (15 (15) 3/12)

Croatia (2 teams: 106 (129) 15/91)
Zagreb, Clinic Hospital 'Merkur', CIC 159, B Jaksic, H Minigo (30 (30) 3/27)
Zagreb, University Hospital Center Rebro, CIC 302, B Labar, D Nemet, M Mrsic (76 (99) 12/64)

Cyprus (1 team: 16 (16) 0/16)
Nicosia Makarios Hospital III (hem), CIC 575, A Papatryfonos (16 (16) 0/16)

Czech Republic (9 teams: 452 (586) 148/304)
Brno, Masaryk University Hospital (ads, peds, hem, onco), CIC 597, J Vorlicek, J Mayer, Z Koristek (94 (148) 19/75)
Hradec Kralové, Charles University (hem), CIC 729, S Filip, M Blaha (41 (55) 11/30)
Olomouc, University Hospital (hem, onco), CIC 574, K Indrak (52 (65) 13/39)
Pilsen, Faculty Hospital (hem, onco), CIC 718, V Koza (69 (83) 32/37)
Prague, Clinical Haematology, Charles University, CIC 318, T Kozak (44 (44) 0/44)
Prague, Thomayer Memorial Hospital, CIC 375, J Abrahamova, J Nepomucká (4 (4) 0/4)
Prague, University Hospital Motol (peds), CIC 656:2, P Sedlacek (42 (58) 31/11)
Prague, Institute of Hematology and Blood Transfusion, CIC 656:1, A Vitek, P Kobylka (43 (56) 42/1)
Prague, Charles University, CIC 745, M Trneny (63 (73) 0/73)

Denmark (3 teams: 227 (260) 60/167)
Aarhus, Amtssygehus (hem), CIC 634, E Segel (55 (58) 0/55)
Copenhagen, Rigshospitalet (hem), CIC 206, N Jacobsen (133 (160) 60/73)

Copenhagen, Herlev Hospital (hem), University, CIC 568, B Jensen (39 (42) 0/39)

Estonia (1 team: 22 (22) 5/17)

Tartu, University Hospital (hem, onco), CIC 746, H Everaus, A Kaare (22 (22) 5/17)

Finland (7 teams: 272 (305) 91/181)

Helsinki, Children's Hospital, CIC 219, U Pihkala, S Vettenranta (26 (29) 15/11)

Helsinki, University Hospital, Dept. of Medicine, CIC 515, T Ruutu (93 (98) 63/30)

Helsinki, University Hospital (onco), CIC 833, H Joensuu, R Janes (10 (10) 0/10)

Kuopio, Department of Medicine, University Hospital, CIC 396, E Jantunen, T Nousiainen (37 (37) 0/37)

Oulu, University Central Hospital (hem, onco), CIC 690, P Koistinen, T Turpeenniemi-Hujanen (35 (42) 0/35)

Tampere, University Hospital (ads, peds), CIC 635, E Koivunen, T Lehtinen, R Silvennoinen, M Arola (27 (40) 0/27)

Turku, University Central Hospital, CIC 225, K Remes (44 (49) 13/31)

France (74 teams: 3289 (3972) 768/2521)

Amiens, CHU Amiens, CIC955, G Damaj (32 (36) 0/32)

Angers, Centre Hospitalier, CIC 650, N Ifrah, S François (59 (74) 9/50)

Angers, Paul Papin, Dr Gamelin (no report)

Argenteuil, Centre hospitalier, M Urbajtel (11 (15) 0/11)

Besançon, Hôpital Jean Minjot & Hôpital St Jacques (ads, peds), CIC 233, P Herve, E Deconinck, P Rohrlisch (68 (86) 29/39)

Brest, Centre Hospitalier, C Berthou (72 (88) 20/52)

Caen, Centre Hospitalier Régional, O Reman (28 (35) 7/21)

Caen, Hôpital Cote de Nacre (peds hem onco), P Boutard (0 (0) 0/0)

Caen, Centre Régional François Baclesse, AM Peny (25 (36) 0/25)

Clermont Ferrand, Centre Jean Perrin and CHU Hotel Dieu (ads, peds), CIC 273 + 589, J-O Bay, F Démeocq, P Travade (87 (114) 18/69)

Colmar, Hôpital civil, B Audhuy (10 (12) 0/10)

Corbeil Essonne, Hôpital Gilles de Corbeil, A Devidas (11 (12) 0/11)

Créteil, Hôpital H. Mondor (hem), CIC 252, C Cordonnier, M Kuentz (38 (40) 21/17)

Dijon, Hôpital d'Enfants, D Caillot (65 (75) 0/65)

Dunkerque, Centre Hospitalier (hem), M Wetterwald (12 (16) 0/12)

Grenoble, Centre Hospitalier A Michallon (ads, allo peds), CIC 270, JY Cahn, F Garban, P Drillat (60 (79) 14/46)

Grenoble, Centre Hospitalier (auto peds), D Plantaz, M Bost (5 (5) 2/3)

Lille, Hôpital Claude Huriez, CIC 277, F Bateurs, JP Jouet (95 (118) 40/55)

Lille, Hôpital Jeanne de Flandre, Dr Nelken (1 (2) 0/1)

Lille, Centre Oscar Lambret (onco), Dr Depadt, Dr Defachelles (22 (25) 0/22)

Lille, Centre Hospitalier Saint Vincent, N Cambier (26 (26) 0/26)

Limoges, Centre Hospitalier Dupuytren (ads, hem), CIC 977, D Bordessoule, P Turlure (49 (56) 0/49)

Lyon, Centre Léon Bérard, CIC 241, P Biron, T Philip (48 (60) 0/48)

Lyon, Hôpital Edouard Herriot, CIC 671, M Michallet, E Wattel, A Thiebaut, F Nicolini, J Troncy, X Thomas (54 (82) 24/30)

Lyon Sud (Pierre Benite), Centre Hospitalier, B Coiffier (166 (166) 0/166)

Lyon, Hôpital Debrousse, C Galambrun, Y Bertrand (22 (22) 21/1)

Marseille, Inst. Paoli-Calmettes, CIC 230, D Blaise (255 (338) 35/220)

Marseille, Hôpital d'Enfants de la Timone (onco), CIC 301, C Coze, JL Bernard (10 (10) 0/10)

Meaux, Centre Hospitalier de Meaux, C Soussain (no report)

Metz, Thionville Hôpital Notre-Dame de Bon-Secours (hem), V Dorvaux, B Christen (26 (31) 0/26)

Montpellier, CHU de Montpellier Hôpital Arnaud de Villeneuve, F Bernard (6 (6) 3/3)

Montpellier, Centre Rég. De Lutte contre de Cancer, M Fabbro, J-B Dubois (11 (11) 0/11)

Montpellier, CHR Lapeyronie (hem), CIC 926, JF Rossi (120 (135) 11/109)

Mulhouse, Hôpital du Hasenrain, B Drénou, M Ojeda (14 (15) 0/14)

Nancy, Vandoeuvre-les-Nancy, Hôpital d'Enfants, P Bordigoni (50 (64) 39/11)

Nancy, Vandoeuvre-les-Nancy, CHU Nancy-Brabois (hem auto), P Lederlin, F Witz (57 (68) 0/57)

Nantes, Hotel Dieu (hem), CIC 253, JL Harousseau, N Milpied (128 (179) 25/103)

Nice, Hôpital de l'Archet (incl. Hôpital Lenval (peds), CIC 523, JP Cassuto, N Gratecos, D de Ricaud (42 (51) 19/23)

Nice, Centre Antoine Lacassagne, A Thyss (28 (31) 0/28)

Paris, Hôpital Necker (ads, hem), CIC 160, B Varet, C Bélanger, A Veil (81 (88) 37/44)

Paris, Hôpital Necker des enfants malades (allo), CIC 201, A Fischer (29 (36) 28/1)

Paris, Hôpital St Louis (hem allo, ads, peds), CIC 207 + CIC 748, E Gluckman, H Esperou, A Baruchel, M-F Auclerc (88 (103) 88/0)

Paris, Hôpital St Louis (auto), CIC 805, G Gisselbrecht (66 (66) 0/66)

Paris, Hôpital St Louis (auto-leuk), CIC 960, H Dombret, L Degos, P Rousselot (no report)

Paris, Hôpital St Louis (auto immuno-Haem), J-P Femand (62 (66) 0/62)

Paris, Hôpital St Antoine (hem), CIC 213, C Gorin, L Fouillard (42 (52) 8/34)

Paris, Hôpital D'enfants Armand-Trousseau, CIC 213, G Leverger, A Auvrignon, L Douay (17 (18) 0/17)

Paris, Hôtel Dieu (hem), CIC 222, Z Marjanovic (56 (68) 24/32)

Paris, Hôpital Pitié Salpêtrière (hem), CIC 262, J-P Vernant, V Leblond, N Dedhin (91 (94) 43/48)

Paris, Institut Curie (ads/onco/peds), CIC 702, J Michon (no report)

Paris, Hôpital Tenon (onco), CIC 747, JP Lotz (28 (49) 0/28)

Paris, Hôpital Robert Debré, K Yakouben, A Baruchel (17 (17) 16/1)

Paris, Hôpital Européen G.P., JM Andrieu, C Le Maignan (8 (8) 0/8)

Paris, Hotel Dieu (onco), Professor Bernadou, L Chauvenet (0 (0) 0/0)

Paris, Hôpital d'Instruction des Armées Percy, Clamart, T de Revel, G Nedellec (35 (41) 11/24)

Paris, Hôpital Cochin (auto), F Dreyfus, M Quarre (38 (40) 0/38)

Pessac, Hôpital Haut-Lévêque, CHU Bordeaux, CIC 267, J Reiffers, G Marit, R Tabrizi (129 (176) 43/86)

Poitiers, Hôpital la Milettrie, CIC 264, M Renaud (79 (100) 22/57)

Pontoise, Hospital René Dubois (onco), CIC 961, F Moruan (14 (16) 0/14)

Reims, Hôpital Robert Debré (hem, onco), CIC 959, B Pignon, C Himberlin (19 (23) 0/19)

Rennes, CHRU, Clinique Médical Infantile, E Le Gall, V Gandemer (4 (4) 1/3)

Rouen, Centre Henri Becquerel, H Tilly, P Lenain (59 (76) 12/47)

Rouen, Hôpital Charles Nicolle, JP Vannier (15 (15) 9/6)

St Cloud, Centre René Huguenin, CIC 551, M Janvier (12 (12) 0/12)

Strasbourg, Hôpital de Haute-pierre, B Lioure (83 (99) 24/59)

Strasbourg, Hospices Civils, Service de Pédiatrie 5, P Lutz (11 (17) 8/3)

Toulouse, Hôpital de Purpan (hem), CIC 624, M Attal, J-C Nogaro (119 (147) 25/94)

Toulouse, Hôpital de Purpan (peds), CIC 624, H Rubie (6 (6) 2/4)

Toulouse, Centre Claudius Régaud, H Roche, C Chevreau (16 (32) 0/16)

Tours, Hôpital Bretonneau (onco), CIC 272, P Colombat (64 (64) 0/64)

Valenciennes, Hosp De Valenciennes, M Simon (no report)

Villejuif, Institut G Roussy (peds), CIC 503, O Hartmann, D Valteau-Couanet (65 (95) 0/65)

Villejuif, Institut G Roussy (ads, hem), CIC 666, J-H Bourhis, C Boccaccio, J-M Vantelon (120 (120) 30/90)

Villejuif, Hôpital Paul Brousse, B Delmas-Marsalet (3 (5) 0/3)

Georgia: no report

Germany (106 teams: 3957 (5203) 1513/2444)

Aachen, Universitätsklinikum RWTH (hem, onco), Med Klinik IV, CIC 348, R Osieka, G Gehbauer (10 (13) 0/10)

Augsburg, Zentralklinikum (hem, onco), Med Klinik II, G Schlimok, M Sandherr (34 (41) 5/29)

Bad Saarow, Humaine Klinikum, G Schultze, U Wruck, K Senftleben (11 (12) 0/11)

Berlin, Universitätsklinikum der HU Charité Campus Virchow Klinikum (peds), CIC 336, G Gaedicke, W Ebell, J Kühl (28 (34) 19/9)

Berlin, Universitätsklinikum der HU Charité Campus Virchow Klinikum (ads, hem, onco), CIC 807, B Dörken, R Arnold (103 (118) 62/41)

Berlin, HELIOS Klinikum Berlin, Robert-Rössle Klinik (hem, onco), CIC 518, W-D Ludwig, R Bargon (27 (34) 0/27)

Berlin, Universitäts-Klinik der FU Benjamin Franklin (hem, onco), CIC 590, E Thiel, L Uharek (61 (83) 27/34)

Berlin, Krankenhaus Neukölln (hem, onco), AC Mayr, C Kerschgens (0 (0) 0/0)

- Bielefeld, Krankenanstalten Gilead (hem, onco), R Kolloch, U Kruempelmann, J Klempin (1 (1) 0/1)
- Bielefeld, Franziska Hospital (hem, onco), HJ Weh, A Zumsprekel (2 (2) 0/2)
- Bochum, Knappschafts-Krankenhaus (hem, onco), W Schmiegel, C Teschendorf (20 (28) 0/20)
- Bonn, Rheinische Friedrich-Wilhelms Universität (ads, hem, onco), T Sauerbruch, I Schmidt-Wolf (26 (26) 0/26)
- Bonn, Rheinische Friedrich-Wilhelms Universität (peds, hem, onco), U Bode, C Hasan (6 (6) 0/6)
- Braunschweig, Städtisches Klinikum (hem, onco), CIC 674, B Wörmann, T Gabrysiak (21 (29) 0/21)
- Bremen, Zentralkrankenhaus St Jürgenstrasse, CIC 602, H Rasche, H Thomssen (16 (23) 0/16)
- Bremen, DIAKO (hem, onco), KH Pflüger, T Wolff (12 (19) 0/12)
- Chemnitz, Krankenhaus Küchwald (hem), CIC 104, M Hänel, G Geissler (65 (85) 0/65)
- Cottbus, Carl-Thiem Klinikum, Med Klinik II (hem), H Steinhauer, N Peter (18 (28) 0/18)
- Dessau, Städtisches Klinikum Dessau (hem, onco), M Plauth, A Florschütz (15 (19) 0/15)
- Dortmund, St Johannes Hospital (hem, onco), H Plelken, M Hindahl (4 (4) 0/4)
- Dresden, Universitätsklinikum Carl Gustav Carus (hem, onco), CIC 808, G Ehninger, M Bornhäuser (172 (208) 114/58)
- Duisburg, St Johannes Hospital, CIC 519, C Aul, R Hartwig (29 (50) 0/29)
- Düsseldorf, Heinrich-Heine Universität; Medizinische Klinik (hem, onco) and St Antonius Hospital, Eschweiler, (hem, onco), CIC 390, R Haas, G Kobbe, R Fuchs (91 (115) 36/55)
- Düsseldorf, Heinrich-Heine Universität; Zentrum für Kinderheilkunde, CIC 651, U Göbel, D Dilloo (24 (34) 17/7)
- Erlangen, Universitäts-Klinik für Kinder und Jugendliche (hem, onco), CIC 809, W Rascher, W Holter, D Stachel (22 (24) 13/9)
- Erlangen, Universität Erlangen-Nürnberg (hem, onco), Med Klinikum III, CIC 809, J-R Kalden, W Rösler (38 (43) 9/29)
- Essen, Universitätsklinikum (ads, peds), CIC 259, DW Beelen, R Peceny, W Havers, B Kremens, O Basu (166 (182) 144/22)
- Essen, Evangelisches Krankenhaus Essen-Werden GmbH (hem, onco), CIC 784, W Heit, M Wattad (36 (39) 0/36)
- Essen, Universitätsklinikum (hem), C Dührsen, R Noppeney (29 (43) 0/29)
- Essen, West German Cancer Center, S Seeber, T Moritz (48 (106) 0/48)
- Frankfurt a.M., Universitätsklinikum dJW Goethe (hem, onco peds), CIC 138, T Klingebiel (22 (28) 14/8)
- Frankfurt a.M., JW Goethe-Universität (ads), CIC 297, D Hoelzer, H Martin (63 (86) 18/45)
- Frankfurt, KH Nordwest, A Knuth, E Jäger (6 (6) 0/6)
- Frankfurt/Mainz, Städtisches Klinikum (ads), HG Derigs, T Flohr (4 (4) 0/4)
- Frankfurt, Klinikum Frankfurt (Oder), CIC 190, M Kiehl (2 (2) 0/2)
- Freiburg i Br, Universitätsklinik (ads, hem, onco), Med Klinik I, CIC 810, R Mertelsmann, J Finke, M Engelhardt (137 (165) 64/73)
- Freiburg i Br, Universitätskinderklinik (hem, onco), CIC 810, C Niemeyer, U Duffner (24 (28) 20/4)
- Giesen, Universitätskinderklinik (hem, onco), CIC 326, A Reiter, W Wössmann (17 (17) 13/4)
- Göttingen, Georg-August Universität (hem, onco), CIC 552, L Trümper, B Glass (74 (104) 34/40)
- Greifswald, Ernst-Moritz-Arndt Universität (ads + peds), CIC 530, G Dölken, W Krüger (32 (36) 15/17)
- Gütersloh, Städtisches Krankenhaus (hem, onco), C Gropp, S Rösler (1 (1) 0/1)
- Hagen, Kath. Krankenhaus (hem, onco), CIC 536, H Eimermacher, W Lindemann (15 (27) 0/15)
- Halle, Martin Luther Universität (hem, onco, ads), CIC 338, H-J Schmoll, H Wolf (31 (72) 0/31)
- Halle, Martin Luther Universität (hem, onco, peds), CIC 654, G Horneff, J Föll (11 (11) 1/10)
- Hamburg, KH St George (hem, onco), CIC 153, N Schmitz, P Dreger (30 (46) 4/26)
- Hamburg, Allgemeines Krankenhaus Altona (hem, onco), CIC 366, D, Braumann, H Salwender (44 (62) 0/44)
- Hamburg, Eppendorf-Krankenhaus (hem, onco, ads, peds) CIC 614, AR Zander, N Kröger (112 (143) 87/25)
- Hamburg, Eppendorf-Krankenhaus (hem, onco, ads), Med Klin II, CIC 673, C Bokemeyer (21 (34) 0/21)
- Hameln, Kreiskrankenhaus Hameln (hem, onco), H Schmidt, K Buhrmann (10 (13) 0/10)
- Hamm, St Marien Hospital (hem, onco), H Dürk, H Pelz (6 (6) 0/6)
- Hamm, Evangelisches Krankenhaus (hem, onco), CIC 509, L Balleisen (21 (21) 0/21)
- Hannover, Medizinische Hochschule (hem, onco, ads), CIC 295, A Ganser, B Hertenstein (77 (102) 48/29)
- Hannover, Medizinische Hochschule (hem, onco, peds), CIC 295, K Welte, K Sykora (29 (36) 21/8)
- Hannover, KH Siloah, CIC 342, H Kirchner, M Sosada (10 (10) 0/10)
- Heidelberg, Ruprecht-Karls Universitäts-Poliklinik (hem, onco), CIC 524, AD Ho, U Hegenbart (188 (279) 20/168)
- Homburg/Saar, Universität des Saarlandes (hem, onco), CIC 785, M Pfreundschuh, J Schubert (52 (73) 14/38)
- Idar-Oberstein, Klinik für Hämato-/Onkologie, CIC 592, AA Fauser, L Kraut (39 (45) 33/6)
- Jena, Klinik der FSU (hem, onco), Innere Medizin II, CIC 533, K Hoeffken, HG Sayer (53 (66) 30/23)
- Jena, Klinikum der FSU (hem, onco), Universitäts-Kinderklinik, CIC 750, F Zintl, D Fuchs (17 (26) 13/4)
- Kaiserslautern, Westfalzklinikum (hem), CIC 357, H Link, F-G Hagmann (8 (13) 0/8)
- Karlsruhe, Städtisches Klinikum (hem, onco), CIC 290, M Bentz, S Wilhelm (7 (12) 0/7)
- Kassel, Städtische Kliniken (hem, onco), M Wolf, E Steinhauer (8 (8) 0/8)
- Kiel, Christian-Albrechts-Universität (hem, onco), CIC 256, M Gramatzki, R Repp (65 (79) 39/26)
- Köln, Universitäts-Klinik (ads, peds), CIC 534, V Diehl, Ch Scheid, F Berthold, T Simon (86 (101) 23/63)
- Krefeld, Klinikum Krefeld, Med Klinik III, T Frieling, S Helmer (13 (17) 0/13)
- Leipzig, Universitäts-Klinik (hem, onco), CIC 389, D Niederwieser, W Pönisch, R Krahl (122 (139) 76/46)
- Lemgo, Klinikum Lippe, HP Lohrmann, C Constantin (9 (9) 0/9)
- Lübeck, Med Universität (ads), CIC 367:1, H Fehm, S Peters (17 (22) 0/17)
- Lübeck, Med Universität (peds), CIC 367:2, P Bucszy, P Temming (2 (4) 0/2)
- Lübeck, Städtisches KH Sud (hem, onco), Dr Heer-Sonderhoff, S Fetscher, A Heer-Sonderhoff (13 (13) 0/13)
- Magdeburg, Otto-von-Guericke Universität (hem, onco), CIC 359, A Franke, M Koenigsmann (26 (38) 0/26)
- Mainz, Johannes-Gutenberg-Universität (hem), Med Klin III, CIC 786, K Kolbe, D Wehler (72 (91) 34/38)
- Mannheim, III Med Klinik, R Hehlmann, J Hastka, E Lengfelder (8 (15) 0/8)
- Marburg, Med Universitätsklinik der Philipps Universität (hem, onco), CIC 645, A Neubauer, J Beyer (48 (64) 20/28)
- Minden/Westfalen, Med Klinik (hem, onco), H Bodenstein, HJ Tischler (12 (20) 0/12)
- Mönchengladbach, KH Maria Hilf II, U Graeven, D Kohl (10 (24) 0/10)
- Munich, Klinikum Grosshadern der LMU (ads, hem, onco) CIC 513, W Hiddemann, H-J Kolb (94 (141) 61/33)
- Munich, Klinikum Innenstadt der LMU (peds, hem, onco), CIC 513, C Bender-Götze (28 (34) 18/10)
- Munich, SKH München-Harlaching (hem, onco), CIC 664, R Hartenstein, M Hentrich (13 (28) 0/13)
- Munich, Städt Krankenhaus, CIC 189, Schwabing (hem, onco, peds), S Burdach, A Wawer, M Nathrath (10 (14) 7/3)
- Munich, Klinikum Innenstadt der LMU, M Reincke, C Straka (40 (55) 0/40)
- Munich, SKH München-Schwabing (hem, onco), Ch Nerl, C Waterhaus, N Fischer (27 (35) 1/26)
- Munich, Klinikum rechts der Isar (hem, onco), CIC 558, C Peschel, Cv Schilling (53 (66) 7/46)
- Münster, Westfälische Wilhelms-Universität Kinderklinik (hem, onco), CIC 505, H Jürgens, J Vormoor (27 (33) 21/6)
- Münster, Westfälische Wilhelms-Universität Klinik (hem, onco), Innere Med CIC 680, W Berdel, J Kienast (92 (112) 37/55)
- Neuss, Lukaskrankenhaus (hem, onco), P Czygan, J Streuss (0 (0) 0/0)
- Nürnberg, Städt Klinikum (hem, onco), CIC 625, M Wilhelm, H Wandt, K Schäfer (47 (70) 18/29)
- Oldenburg, Klinikum Oldenburg (hem, onco), CIC 749, C Köhne, B Metzner (44 (74) 0/44)

Potsdam, Klinikum Ernst von Bergmann (hem, onco), R Pasold, A Haas (17 (18) 0/17)
 Regensburg, Universitäts Klinikum (hem, onco), CIC 787, R Andreesen, E Holler, A Reichle (89 (119) 37/52)
 Rostock, Universitäts Klinikum (hem, onco), CIC 585, M Freund, J Casper (40 (75) 10/30)
 Siegen, St Marien Krankenhaus (hem, onco), CIC 135, W Gassmann, T Gaska (18 (19) 0/18)
 Stuttgart, Robert-Bosch-Krankenhaus (hem, onco), CIC 145, W Aulitzky, S Martin (46 (57) 5/41)
 Stuttgart, Olgahospital (hem, onco), Pädiatrisches Zentrum, CIC 701, J Treuner, E Koscielniak (5 (5) 0/5)
 Stuttgart, Bürgerhospital and Katharinenhospital (onco), H Mergenthaler, W Grimminger, J Schleicher (25 (36) 0/25)
 Stuttgart, Diakonissen Krankenhaus, E Heidemann, M Bichler (11 (13) 0/11)
 Tübingen, Medizinische Universitäts-Klinik (hem, onco), CIC 223, L Kanz, H Einsele, C Faul (101 (145) 39/62)
 Tübingen, Medizinische Universitäts-Klinik (hem, onco), Abteilung Pädiatrie, CIC 535, D Niethammer, J Greil (31 (39) 19/12)
 Ulm, Medizinische Universitäts-Klinik (hem, onco), CIC 204, H Döhner, D Bunjes (121 (149) 51/70)
 Ulm, Kinderklinik der Universität, CIC 204, K Debatin, W Friedrich, A Schultz (27 (30) 27/0)
 Villingen, Klinikum Villingen- Schwenningen, W Brugger, F Köhles, W Willenbacher (11 (11) 0/11)
 Wiesbaden, Deutsche Klinik für Diagnostik, CIC 311, R Schwerdtfeger, M Schleuning, H Baumann (79 (85) 67/12)
 Wiesbaden, Dr Horst-Schmidt Klinikum (hem, onco), CIC 586, N Frickhofen, B Jung (12 (20) 0/12)
 Wuppertal, HELIOS Klinikum Wuppertal (hem, onco), A Raghavachar (0 (0) 0/0)
 Würzburg, Universitätsklinikum Würzburg (hem, onco, ads), CIC 712, K Wilms, F Weissinger, P Reimer (32 (43) 1/31)
 Würzburg, Universitätsklinikum Würzburg (peds), CIC 196, P Schlegel (8 (10) 0/8)

Greece (12 teams: 262 (283) 85/177)

Alexandroupolis, Thrace University Medical School (Haem), CIC 681, G Bourikas, D Pantelidou (5 (5) 0/5)
 Athens, Laikon General Hospital, CIC 328, Y Rombos, D Boutsis, V Kalotychoy (21 (21) 0/21)
 Athens, Medical Center (hem), CIC 603, A Pigadito (no report)
 Athens, University of Athens, CIC 604, I Dervenoulas (13 (13) 1/12)
 Athens, Evangelismos Hospital (hem), CIC 622, D Karakassis, N Harhalakis, E Nikiforakis (54 (60) 33/21)
 Athens, General Hospital G Gennimatas (hem), CIC 638, A Skandalis (14 (14) 0/14)
 Athens, Diagnosis & Therapy Centre 'Hygeia' (hem), Maroussi, CIC 643, G Karianakis (11 (11) 0/11)
 Athens, Hellenic Cancer Institute St Savas (onco), CIC 751, A Efremedis, G Koumakis, M Stamatellou, K Papanastassiou, I Fillis (31 (39) 2/29)
 Athens, 'Aghia Sophia' Children's Hospital, CIC 752, S Graphakos (30 (31) 20/10)
 Crete, University Hospital of Heraklion (peds, hem-onco), CIC 352, M Kalmanti (1 (1) 0/1)
 Patras, University Medical School (hem), CIC 281, NC Zoumbos, M Tiniakou (22 (25) 7/15)
 Thessaloniki, The George Papanicolaou General Hospital (hem), CIC 561, AS Fassas (60 (63) 22/38)

Hungary (5 teams: 198 (204) 53/145)

Budapest, National Medical Centre (hem ads), CIC 556, T Masszi, A Batai, P Remenyi (33 (36) 12/21)
 Budapest, Szent Laszlo Hospital (peds), CIC 824, G Krivan, E Torbvagy, L Lengyel (99 (102) 30/69)
 Debrecen, University of Debrecen, CIC 648, A Kiss (12 (12) 0/12)
 Miskolc, Postgraduate Medical School (peds), CIC 599, N Kalman, G Marton (17 (17) 11/6)
 Pécs, University of Pécs, Internal Medicine, CIC 682, H Losonczy, M Dávid, Á Szomor (37 (37) 0/37)

Iceland (1 team: 7 (7) 0/7)

Reykjavik, National University Hospital (hem), CIC 605, S Reykdal (7 (7) 0/7)

Iran (2 teams: 260 (267) 184/76)

Shiraz, Nemazee Hospital (hem, onco), CIC 188, M Ramzi (27 (27) 24/3)
 Teheran, Shariati Hospital (hem, onco), CIC 633, A Ghavamzadeh (233 (240) 160/73)

Ireland (5 teams: 113 (114) 47/66)

Cork, University Hospital, M Cahill (4 (4) 0/4)
 Dublin, St James's Hospital (hem), CIC 257, SR McCann (79 (80) 37/42)
 Dublin, St Vincent's Hospital (hem, onco), CIC 541, J Crown, K Murphy (7 (7) 0/7)
 Dublin, Our Lady's Hospital of Sick Children, Crumlin, CIC 774, A O'Meara (14 (14) 10/4)
 Galway, University College Hospital, M Murray (9 (9) 0/9)

Israel (7 teams: 480 (548) 231/249)

Haifa, Rambam Medical Center (hem, ads, peds), CIC 345, J Rowe (138 (150) 60/78)
 Jerusalem, Hadassah University Hospital (ads, peds), CIC 258, R Or, S Slavin (100 (117) 60/40)
 Petach-Tikva, Children's Medical Center, CIC 755, J Stein (39 (40) 23/16)
 Revohot, Kaplan Hospital (hem), CIC 327, A Berribi (11 (12) 0/11)
 Tel Aviv, Sourasky Medical Center, CIC 161, E Naparstek (26 (35) 9/17)
 Tel Hashomer, Chaim Sheba Medical Center (hem, onco, ads) CIC 754, A Nagler, A Shimoni (141 (166) 63/78)
 Tel Hashomer, Chaim Sheba Medical Center (hem, onco, peds) CIC 572, A Toren, H Golan, B Bielorai (25 (28) 16/9)

Italy (96 teams: 3527 (4517) 1004/2523)

Alessandria, SS Antonio e Biagio e C Arrigo (hem), CIC 825, A Levis, A Allione, M Pini, F Salvi (31 (41) 9/22)
 Ancona, Nuovo Ospedale Torrette (hem), CIC 788, P Leoni, A Olivieri (47 (56) 10/37)
 Avellino, AOS Giovanni Di Guglieimo (hem), CIC 789, N Cantore, G Storti (30 (33) 2/28)
 Avezzano, Ospedale Civile di Avezzano, F Recchia (5 (5) 0/5)
 Aviano, CRO Aviano (onco), CIC 162, M Michieli, M Rupolo, M Mazzucato, F Lollo (40 (53) 0/40)
 Bari, Università degli Studi di Bari (hem), CIC 649, V Pavone, V Liso (33 (33) 15/18)
 Bergamo, Ospedale Riuniti, CIC 658, T Barbui, A Rambaldi (73 (98) 18/55)
 Bologna, St Orsola-Malpighi (hem, onco), CIC 240, G Bandini, F Bonifazi, M Baccarani (142 (172) 41/101)
 Bologna, St Orsola-Malpighi, Oncologia Medica, CIC 657, A Martoni, C Zamagni (6 (10) 0/6)
 Bologna, Poli S Orsola, Clinica pediatrica III, CIC 790, A Pession (25 (35) 14/11)
 Bolzano, Ospedale S Maurizio (hem), CIC 299, M Casini, P Fabris, P Coser (48 (80) 6/42)
 Brescia, Ospedali Civili, CIC 288, G Rossi, C Almici (73 (98) 0/73)
 Brescia, Università degli Studi di Brescia (peds), CIC 741, F Porta, A Ugazio (22 (25) 17/5)
 Brindisi, Ospedaliera 'A Di Summa', Perrino Hospital (hem), CIC 920, G Quarta, S Pinna (6 (6) 0/6)
 Cagliari, Ospedale A Businco (hem), CIC 791, P Dessalvi (45 (64) 13/32)
 Cagliari, BMT Center CIC 811, G La Nasa (12 (19) 6/6)
 Cagliari, Ospedale per le Microcitemie (peds), CIC 812, F Argiolu, A Cao (11 (13) 9/2)
 Catania, Ospedale Ferrarotto (hem), CIC 792, R Giustolisi, G Milone (35 (46) 10/25)
 Cremona, Ospedale Maggiore (hem), Medicina II, CIC 226, S Morandi, P Spedini, M Tajana, C Fiamenghi (8 (12) 0/8)
 Cuneo, Hospital S Croce E Carle (hem), CIC 606, A Gallamini, N Mordini (20 (34) 7/13)
 Ferrara, St Anna Hospital (hem), CIC 330, G Castoldi, F Lanza, S Moretti, GM Rigolin, R Spanedda (13 (16) 0/13)
 Firenze, Ospedale di Careggi (hem), CIC 304, A Bosi, S Guidi (84 (105) 23/61)
 Firenze, Azienda Ospedale, 'A Meyer', CIC 600, L Faulkner (no report)
 Forlì, Morgagni-Pierantoni Hospital (onco), CIC 298, GL Frassinetti, D Amadori (24 (52) 0/24)

Genova, Università, CIC 139, F Patrone, A Ballestrero (39 (47) 0/39)
 Genova, Ospedale S Martino (hem), CIC 217, A Bacigalupo, G Santini (85 (91) 68/17)
 Genova, Istituto Giannina Gaslini (hem, onco), CIC 274, G Dini (42 (60) 16/26)
 Latina, Ospedale S Maria Goretti, CIC 379, A De Blasio, E Zappone (16 (19) 0/16)
 Messina, Policlinico Universitario (onco), CIC 669, V Pitini (11 (14) 0/11)
 Milano, Ospedale di Niguarda (onco ST), CIC 184, S Siena, P Pedrazzoli, R Schiavo (33 (40) 6/27)
 Milano, Ospedale Maggiore di Milano, CIC 265, G Lambertenghi Delilieri (54 (68) 18/36)
 Milano, Ospedale Fatebenefratelli e Oftalmico (onco), CIC 269, A Scanni, C Bianchi, D Pedretti (0 (0) 0/0)
 Milano, Ospedale di Niguarda (hem), CIC 294, P Marengo, R Cairoli, G Grillo (77 (85) 18/59)
 Milano, Istituto Europeo di Oncologia, CIC 331, G Martinelli (59 (90) 6/53)
 Milano, 1st Clinico Humanitas (hem-onco), CIC 354, A Santoro, L Castagna (45 (95) 3/42)
 Milano, Istituto Nazionale Tumori (ads, onco, peds), CIC 616, A Gianni, P Corradini, R Luksch (118 (152) 15/103)
 Milano, S Carlo Borromeo Hospital (onco), CIC 683, L Tedeschi (6 (6) 0/6)
 Milano, Istituto Scientifico HS Raffaele, CIC 813, M Bregni (70 (128) 25/45)
 Modena, University of Modena (hem, onco), CIC 543, F Narni, A Donelli, R Sabbatini (47 (62) 7/40)
 Monza, Ospedale S Gerardo (peds), CIC 279, C Uderzo (28 (31) 20/8)
 Monza, Ospedale S Gerardo de Tintori, CIC 544, P Pioltelli, E Pogliani (45 (63) 10/35)
 Napoli, Div Di Oncologia, CIC 313, C Battista, G Pacilio, B Chiuazzini, G Iodice (6 (6) 0/6)
 Napoli, Hospital 'Pausilipon' (hem peds), V Poggi, M Ripaldi (12 (12) 7/5)
 Napoli, Cardarelli Hospital (hem), CIC 607, F Ferrara (62 (70) 0/62)
 Napoli, Cardarelli Hospital (hem), CIC 837, V Mettievier (20 (21) 0/20)
 Napoli, Università Federico II (hem), CIC 766, B Rotoli, C Sella, G De Rosa (40 (47) 12/28)
 Noale, Civic Hospital (onco), CIC 563, O Vinante, G Azzarello (no report)
 Nuoro, Ospedale San Francesco (hem), CIC 793, A Gabbas, A Palmas (no report)
 Orbassano, Ospedale San Luigi Orbassano, CIC 378, G Saglio, A Guerrasio (23 (38) 0/23)
 Padova, Centro Leucemie Infantili, CIC 285, C Messina, S Cesaro, L ZanESCO, S Varotto (24 (31) 15/9)
 Padova, Centro Oncologia Regionale, CIC 319, S Aversa, S Monfardini (13 (24) 1/12)
 Palermo, Ospedale die Bambini (peds.hem,onc), CIC 109, D Caselli (6 (7) 1/5)
 Palermo, Ospedale V Cervello (hem), CIC 392, R Scimè, A Cavallaro (60 (81) 17/43)
 Palermo, Ospedale 'La Maddalena' (hem, onco), CIC 692, M Musso, F Porretto, A Crescinanno (48 (66) 14/34)
 Palermo, Azienda Universitaria Policlinico, Uni degli studi di Palermo (hem), CIC 814, E Iannitto (8 (11) 0/8)
 Parma, Cattedra di Ematologia, University of Parma, CIC 245, V Rizzoli (15 (26) 1/14)
 Parma, Ospedaliere Di Parma, CIC 364, V Franciosi, S Cascinu (0 (0) 0/0)
 Pavia, Policlinico S Matteo (hem), CIC 286, EP Alessandrino (68 (69) 23/45)
 Pavia, Policlinico St Matteo (hem, onco, peds), CIC 557, F Locatelli (90 (99) 74/16)
 Pavia, Policlinico St Matteo (onco), CIC 562, M Danova (15 (15) 0/15)
 Pavia, Fondazione S Maugeri (onco), CIC 771, A Zambelli, G Robustelli della Cuna (7 (10) 1/6)
 Perugia, Policlinico Monteluca (onco), CIC 573, AM Liberati, FGrignani (16 (20) 0/16)
 Perugia, Policlinico Monteluca (hem), Università, CIC 794, MF Martelli, F Aversa, A Tabilio (156 (156) 55/101)
 Perugia, Silvestrini Hospital, A Amici (0 (0) 0/0)
 Pesaro, Ospedale San Salvatore, CIC 529, G Visani, G Lucarelli (40 (44) 14/26)
 Pescara, Ospedale Civile (hem), CIC 248, P di Bartolomeo (31 (41) 25/6)
 Piacenza, Ospedale Civile (hem, onco), CIC 163, L Cavanna (17 (20) 1/16)

Pisa, University of Pisa (peds, hem, onco), CIC 795, P Macchia (20 (22) 12/8)
 Pisa, University of Pisa (ads, hem, onco), CIC 132, M Petrini, F Papineschi (42 (58) 12/30)
 Ravenna, Ospedale Civile (hem, onco), CIC 306, G Rosti (41 (58) 0/41)
 Reggio di Calabria, Azienda Ospedale 'Riuniti e Morelli', CIC 587, P Iacopino, G Console (79 (103) 19/60)
 Reggio Emilia, Arcispedale S Maria Nuova (hem), CIC 660, L Gugliotta (24 (29) 4/20)
 Rimini, Ospedale Infermi Rimini (hem.onco), P Fattori (9 (15) 0/9)
 Rionero in Vulture, Ospedale Oncologico Regionale, CIC 185, N Di Renzo (15 (15) 0/15)
 Roma, Regina Elena Cancer Institute (hem, onco), CIC108, M Petti (11 (14) 0/11)
 Roma, Università 'La Sapienza' (hem), CIC 232, R Foa, G Meloni (100 (114) 30/70)
 Roma, Ospedale S Camillo (hem), CIC 287, I Majolino, A Locasciulli (36 (40) 18/18)
 Roma, Università Cattolica (hem), CIC 307, S Cuore, S Sica, G Leone (53 (59) 16/37)
 Roma, Ospedale Bambino Gesù (hem), CIC 315, G De Rossi (13 (13) 10/3)
 Roma, Università S Eugenio (hem), CIC 756, W Arcese, P Fabritiis (64 (67) 29/35)
 Roma, Ospedale Bambino Gesù (onco), CIC 796, A Donfrancesco (14 (24) 0/14)
 San Giovanni Rotondo, Hospital Casa Sollievo Sofferenza (onco), CIC 314, M Aieta (1 (1) 0/1)
 San Giovanni Rotondo, Hospital Casa Sollievo Sofferenza (hem), CIC 526, M Corsetti, M Greco (43 (66) 10/33)
 Sassari, Università Di Sassari (hem) CIC 870, M Longinotti (10 (11) 0/10)
 Siena, Ospedale Sclavo (hem), CIC 321, F Lauria (43 (48) 10/33)
 Taranto, Ospedale Nord (hem), CIC 332, P Mazza, G Palazzo, B Amurri (70 (77) 14/56)
 Torino, Azienda Ospedaliera S Giovanni, CIC 231, M Falda, F Locatelli (89 (120) 35/54)
 Torino, Ospedale Regina Margherita (peds), CIC 305, E Madon, F Fagioli, E Vassallo (39 (51) 20/19)
 Torino, Ospedale Mauriziano Umberto I, IRCC, CIC 377, M Aglietta, A Capaldi, F Carnevale (23 (28) 10/13)
 Torino, Ospedale S Giovanni (hem), CIC 696, M Boccadoro, M Massaia, C Tarella, B Benedetto, D Caracciolo, A Pileri (76 (125) 16/60)
 Trieste, Istituto per l'Infanzia, Clinical Pediatrica, CIC 525, M Andolina (16 (17) 14/3)*
 Udine, Policlinico Universitario (hem), CIC 705, R Fanin (85 (109) 30/55)
 Venezia, Ospedale Civile Riuniti di Venezia (hem), CIC 502, T Chisesi, M Vespignani, M Chinello (27 (41) 2/25)
 Verbania, UOA Oncologia Medica, Ospedale di Verbania, CIC 388, A Luraschi (0 (0) 0/0)
 Verona, Policlinico di Borgo Roma (hem, onco), CIC 623 + CIC 514, G Perona, F Benedetti, G Cetto (56 (62) 16/40)
 Vicenza, Ospedale S Bortolo (hem), CIC 797, R Raimondi, F Rodeghiero (59 (76) 18/41)

Latvia (1team: 10 (10) 0/10)

Riga, Clinic Linezers, CIC 583, S Lejiniece (10 (10) 0/10)
 Liechtenstein: no report

Lithuania (2 teams; 46 (50) 15/31)

Vilnius, University Hospital Santariskiu Klinikos (hem), CIC 644, A Slobinas, I Trociukas (35 (38) 11/24)
 Vilnius, University Children's Hospital (hem, onco), CIC 508, J Rascon (11 (12) 4/7)

Luxemburg: no report

Macedonia (1 team: 24 (24) 7/17)

Skopje, Medical Faculty (hem), CIC 381, B Georgievski (24 (24) 7/17)

Malta: no report

Moldova: no report

Monaco: no report

Netherlands (13 teams: 824 (961) 324/500)

Amsterdam, Academic Medical Center (ads, peds), CIC 247, J van der Lelie, H van den Berg (peds) (47 (59) 13/34)
 Amsterdam, Free University Hospital (hem), CIC 588, GJ Ossenkoppele (83 (105) 21/62)
 Amsterdam, The Netherlands Cancer Institute, S Rodenhuis J Baars (32 (39) 0/32)
 Enschede, The Medisch Spectrum Twente, CIC 360, Dr Schaafsma (23 (24) 0/23)
 Groningen, University Hospital (hem), CIC 546, G van Imhoff, E Vellenga (58 (64) 10/48)
 The Hague, Haga Hospital (Leyenburg), CIC 547, PW Wijermans (32 (38) 0/32)
 Leiden, University Medical Centre (ads, peds), CIC 203, R Willemze, M Egeler (95 (113) 68/27)
 Maastricht, University Hospital (hem, onco), CIC 565, HC Schouten, J Wagstaff (68 (71) 28/40)
 Nieuwegein, St Antonius Hospital, CIC 200, D Biesma, G Veth, O de Weerdt (13 (14) 0/13)
 Nijmegen, University Hospital (ads, peds, onco), CIC 237, A Schattenberg, L Beex, P Hoogerbrugge (101 (121) 48/53)
 Rotterdam, Dr Daniel den Hoed Cancer Center, CIC 246, JJ Cornelissen (134 (144) 51/83)
 Utrecht, University Hospital (hem, ads, peds), CIC 239, LF Verdonck, NM Wulfraat (126 (157) 85/41)
 Zwolle, Isala Klinieken/Sophia Ziekenhuis, CIC 548, M von Marwijk Kooy (12 (12) 0/12)

Norway (5 teams: 114 (124) 44/70)

Bergen, Haukelands Sjukhus, CIC 197, P Ernst (13 (15) 0/13)
 Oslo, Rikshospitalet, CIC 235, D Albrechtsen, L Brinch (59 (67) 44/15)
 Oslo, The Norwegian Radium Hospital (onco), CIC 782, S Kvaloy (no report)
 Oslo, Ullevals Sjukhus (haem), F Wisslöf, J-M Tangen (19 (19) 0/19)
 Trondheim, St Olavs Hospital, J Hammerstrom, A Waage (23 (23) 0/23)

Poland (17 teams: 824 (961) 324/500)

Bydgoszcz, Medical University (peds, hem, onco), CIC 764, M Wysocki, J Styczinski (12 (12) 2/10)
 Gdansk, Medical University (hem), CIC 799, A Hellmann (57 (61) 25/32)
 Katowice, Silesian Medical Academy (hem), CIC 677, J Holowiecki (139 (158) 67/72)
 Krakow, Jagiellonian University (hem), CIC 553, A Skotnicki (45 (49) 15/30)
 Krakow, Polish-American Children's Hospital, JUMC, CIC 507, M Ratajczak (9 (9) 0/9)
 Lodz, Medical University of Lodz (hem), CIC 171, T Robak (23 (23) 0/23)
 Lublin, Children's University Hospital (hem, onco), CIC 678, J Kowalczyk (22 (24) 14/8)
 Lublin, University Medical School (hem, onco), CIC 695, A Dmoszynska, M Wach, A Walter-Croneck, W Legiec (32 (37) 0/32)
 Poznan, Institute of Pediatrics, CIC 641, J Wachowiak (18 (20) 18/0)
 Poznan, K Marcinkowski University (hem), CIC 730, M Komarnicki (58 (62) 21/37)
 Warsaw, Institute of Haematology and Blood Transfusion, CIC 693, B Marianska, L Konopka, B Nasilowska (14 (16) 5/9)
 Warsaw, Maria Skłodowska-Curie, Centre of Oncology, CIC 800, J Walewski (41 (49) 0/41)
 Warsaw, Central Hospital Military Medical Academy (hem, onco), CIC 816, P Rzepecki, K Sulek, C Szczylik (36 (37) 9/27)
 Warsaw, Central Clinical Hospital (hem, onco), CIC 954, W Wiktor-Jedrzejczak, A Deptala, M Rokicka (46 (63) 14/32)
 Wrocław, Lower Silesian Centre for Cellular Transplantation with National Bone Marrow Donor Registry, CIC 538, A Lange (64 (66) 35/29)
 Wrocław, Medical Academy (hem), CIC 699, K Kuliczowski (19 (19) 4/15)
 Wrocław, University of Medicine (peds, hem, onco), CIC 817, A Chybicka (62 (67) 47/15)

Portugal (6 teams: 256 (279) 85/171)

Coimbra, University Hospital, CIC 164, N Costa (20 (20) 0/20)
 Lisbon, Instituto Portugues de Oncologia, CIC 300, M Abecasis, F Leal Costa (71 (78) 29/42)

Lisbon, Hospital de Santa Maria, CIC 636, J Alves do Carmo, F de Lacerda (36 (43) 27/9)
 Lisbon, Hospital de St Antonio dos Capuchos, CIC 826, A Botelho de Sousa (36 (38) 0/36)
 Porto, Instituto Portugues de Oncologia, CIC 291, P Pimentel, F Campilho (67 (73) 29/38)
 Porto, Hospital S Joao (hem.onco), CIC 329 (merged with CIC 572, F Principe, JE Guimaraes (26 (27) 0/26)

Romania (3 teams: 17 (17) 4/13)

Bucharest, Fundeni University Hospital (hem), CIC 296, AD Moicean, D Colita, C Arion (7 (7) 3/4)
 Targu-Mures, Sectia Clinica de Hematologie, CIC 178, I Benedek (7 (7) 0/7)
 Timisoara, University of Medicine (Ill peds Hem/Onco), CIC 174, M Serban (3 (3) 1/2)

Russia (13 teams: 211 (225) 76/135)

Ekaterinburg, City Hospital no. 7, LB Filatov (1 (1) 0/1)
 Ekaterinburg, Regional Hospital no. 1, TS Konstantinova, VA Shalaev (14 (16) 1/13)
 Moscow, Russian Children's Hospital (hem), CIC 694, A Maschan, E Skorobogato, E Pachanov (37 (41) 32/5)
 Moscow, Cancer Research Center, CIC 757, V Ptuschkina (36 (40) 0/36)
 Moscow, Institute of Biophysics, AE Baranov (0 (0) 0/0)
 Moscow, Cancer Research Center peds Hem/onco, G Mentrevich (23 (23) 10/13)
 Moscow, Research Hematology Center of RAS, VG Savtchenko (26 (29) 15/11)
 Novosibirsk, Insitute of Clinical Immunology, CIC 376, I Lisukov (26 (26) 1/25)
 Samara, Regional Hospital, VA Rossiev (7 (7) 0/7)
 St Petersburg, Clinical Center for Advanced Medical Tech, CIC 370, E Podoltseva, V Soldatenkov, O Rysanyanskaya (no report)
 St Petersburg, Military Medical Academy (hem), CIC 520, A Novik (no report)
 St Petersburg, Research Institute of Hematology, KM Abdulkadirov (4 (4) 3/1)
 St Petersburg, State Pavlov Medical University (hem), CIC 725, BV Afanassiev, L Zubarovskaya (37 (38) 14/23)
 San Marino: no report

Saudi Arabia (2 teams: 203 (205) 150/53)

Riyadh, King Faisal Specialist Hospital and Research centre (onco, ads hem), CIC 397.1, MAI Jurf (124 (124) 78/46)
 Riyadh, King Faisal Specialist Hospital and Research centre (peds hem, onco), CIC 397.2, M Ayas (79 (81) 72/7)

Slovakia (4 teams: 144 (156) 42/102)

Banska Bystrica, Roosevelt Hospital (hem), CIC 333, I Markuljak, E Kralikova (15 (20) 0/15)
 Bratislava, National Cancer Institute, CIC 560, J Lakota (85 (91) 20/65)
 Bratislava, University Hospital (hem), CIC 610, M Mistrík (28 (29) 13/15)
 Bratislava, University Hospital, 2nd Children's Clinic, CIC 684, J Horáková, S Sufliarska, I Bodova (16 (16) 9/7)

Slovenia (1 team: 54 (67) 21/33)

Ljubljana, University Medical Centre (hem), CIC 640, J Pretnar (54 (67) 21/33)

Spain (71 teams: 1675 (1855) 421/1254)

Alicante, Hospital General, C Rivas-Gonzales (no report)
 Barcelona, Hospital Clinic (hem, onco), CIC 214, E Montserrat, E Carreras (58 (64) 21/37)
 Barcelona, Santa Creu I Sant Pau (adults), CIC 260, J Sierra, S Brunet (89 (110) 39/50)
 Barcelona, Santa Creu I Sant Pau (peds), CIC 260, I Badell Serra, J Cubells-Riero (8 (10) 2/6)

Barcelona, Hospital M Infantil, CIC 527, T Olivé, J Ortega (37 (39) 19/18)
 Barcelona, Hospital Mutua de Terrasa (hem-onco), T Marti (no report)
 Barcelona, Hospital General 'Vall d'Hebron', CIC 527, A Julia Font, J Zuazu (32 (35) 13/19)
 Barcelona, Hospital Universitario Germans Trias i Pujol, CIC 613, J Ribera (50 (53) 18/32)
 Barcelona, Hospital Sant Joan de Deu, CIC 668, J Estella Aguado (7 (7) 0/7)
 Barcelona, Hospital Duran i Reynals (Hem), Institut Catala d'Oncologia, CIC 759, C Ferrá, J Berlanga, A Fernández (32 (33) 8/24)
 Barcelona, Instituto de Oncologia Corachan, D Alfonso-Modolell (0 (0) 0/0)
 Caceres, Hospital San Pedro de Alcantara, M Luz Amigo Lozano (14 (14) 0/14)
 Cadiz, Hospital del SAS de Jerez (hem), CIC 612, A Leon (22 (32) 4/18)
 Cadiz, Hospital Universitario 'Puerta del Mar' (hem), CIC 679, J Gil (10 (10) 0/10)
 Canary Isles, Las Palmas, Hospital Insular (hem), CIC 335, J Gonzalez-San Miguel (8 (9) 0/8)
 Canary Isles, Las Palmas, Hospital Materno-Infantil (haem, onco), J Lodos Rojas, A Molinés (1 (1) 0/1)
 Canary Isles, Las Palmas, Hospital Universitario de Gran Canaria 'Dr Negrin', CIC 537, T Molero, R Mataix, C Campo, S Jiménez (22 (27) 8/14)
 Canary Isles, Tenerife, Hospital Universitario de Canarias, L Hernandez Nieto, MT Hernandez Garcia (15 (15) 0/15)
 Canary Isles, Tenerife, University Hospital, J Garcia-Talavera, J Breña, P Rios Rull (16 (16) 0/16)
 Castellon de La Plana, Hospital General de Castellon (haem), R Garcia-Boyer (13 (15) 0/13)
 Cordoba, Hospital Reina Sofia (hem), CIC 238, A Torres Gomez (45 (52) 15/30)
 Cordoba, Hospital de la Cruz Roja de Cordoba (haem), J-M Garcia-Castellano (0 (0) 0/0)
 Cruces-Barakaldo, Hospital de Cruces (hem), CIC 393, I Zuazua-Verde, F Floristan (40 (44) 0/40)
 Galdakao, Hospital de Galdakao, Hem, CIC 975, J Ojanguren, K Atutxa (9 (9) 0/9)
 Granada, Hospital Virgen de la Nieves (hem), CIC 559, JM de Pablos Gallego Jaen, Hospital Cuidad de Jaen (haem), A Alcalam (30 (33) 8/22)
 Jaen, Hospital Cuidad de Jaen (haem), A Alcalam (no report)
 La Coruna, Complejo Hospitalario Juan Canalejo, CIC 361, FJ Batlle, C Ramirez, P Torres, A Vale, R Varela (40 (53) 4/36)
 Lérida, Hospital Arnau de Villanova, J Macia (8 (8) 0/8)
 Lugo, Hospital Xeral-Calde, M Gonzales-Lopez (7 (7) 0/7)
 Madrid, Hospital de la Princesa (hem), CIC 236, JM Fernández Rañada, A Figuera, A Alegre (49 (53) 25/24)
 Madrid, Hospital Doce de Octubre, CIC 382, JJ Lahuerta (hem), H Cortés Funes (onco), J Lopez Perez (peds) (60 (65) 9/51)
 Madrid, Hospital Ramon y Cajal (ads), CIC 615, J Odriozola, J Pérez de Oteyza, J Lopez, J Garcia Larana (no report)
 Madrid, Hospital Ramon y Cajal (peds), CIC 615, A Munoz Villa (4 (4) 1/3)
 Madrid, Clinica Puerta de Hierro (hem), CIC 728, MN Fernandez (34 (35) 16/18)
 Madrid, Hospital Nino Jesus (peds), CIC 732, MA Diaz (36 (38) 17/19)
 Madrid, Hospital Universitario San Carlos (hem), CIC 733, J Diaz Mediavilla, L Llorente, R Martínez (30 (30) 0/30)
 Madrid, Hospital La Paz Infantil (hem, onco) and Hospital General La Paz (ads), CIC 734, A Martínez-Rubio, A Sastre, F Hernandez Navarro, M Canales (53 (58) 11/42)
 Madrid, Unidad de TMO-ONC 4, Hospital Gregorio Marañon, CIC 819, JL Diez Martin (35 (39) 7/28)
 Madrid, Clinica Moncloa (hem), JM Fernandez-Ranada, A Escudero (10 (10) 0/10)
 Madrid, Clinica Ruber, JM Fernandez-Ranada, A Escudero (17 (17) 0/17)
 Madrid, Hospital Ruber Internacional (onco), P Aramburo (1 (1) 0/1)
 Madrid, Hospital Universitario de Getafe (hem), F Oña Compan, N Somolinos (15 (16) 0/15)
 Madrid, Fundacion Jimenez Diaz (hem, onco), CIC 309, J Tomas, C Paniagua, F Lobo (19 (20) 2/17)
 Madrid, Hospital Militar Gomez Ulla, F Sancho-Cuesta, S Enrech-Frances (0 (0) 0/0)

Malaga, Hospital Regional (hem), CIC 576, M Gonzalez, M Pascual (38 (38) 7/31)
 Murcia, Hospital University 'Virgen de la Arrixaca', CIC 323, A Morales-Lazaro, MJ Majado-Martinez (12 (12) 0/12)
 Murcia, Hospital Morales Meseguer, CIC 735, JM Moraleda Jimenez, V Vicente-Garcia, I Heras (38 (43) 8/30)
 Orense, Hospital Cristal-Pinor (hem), J-L Sastre-Moral (8 (8) 0/8)
 Oviedo, Hospital Covadonga (hem), CIC 642, D Carrera Fernandez (31 (32) 1/30)
 Palma de Mallorca, Hospital Son Dureta (hem), CIC 722, J Besalduch, M Canaro (36 (37) 7/29)
 Palma de Mallorca, Policlínica Miramar, J Besalduch, A Sampol (0 (0) 0/0)
 Palma de Mallorca, Hospital son Llatzer, CIC 110, J Bargay-Lleonart (9 (10) 0/9)
 Pamplona, Hospital Provincial de Navarra (hem), CIC 577, M Orue, MJ Uriz (18 (20) 0/18)
 Pamplona, Clinica Universitaria de Navarra, CIC 737, J Rifon (30 (33) 2/28)
 Pontevedra, Hospital Montecelo (onco), CIC 549, M Constela (7 (7) 0/7)
 Salamanca, Hospital Clinico (hem), CIC 727, D Caballero (68 (79) 22/46)
 San Sebastian, Hospital Nostra Senora de Aranzazu, CIC 598, R Lasa, J Marin, D Martinez (25 (30) 6/19)
 Santander, Hospital Universitario M de Valdecilla (hem), CIC 242, A Iriondo, E Conde (59 (72) 19/40)
 Santiago de Compostela, Hospital Xeral de Galicia (hem), CIC 570, JL Bello (27 (29) 12/15)
 Sevilla, Hospital Universitario Virgen del Rocío, CIC 769, JM Rodriguez Fernandez (52 (56) 25/27)
 Tarragona, Hospital de Tarragona Joan XXIII (hem), A Llorente Cabrera (16 (16) 0/16)
 Valencia, Hospital Clinico Universitario (hem, onco), CIC 282, J Garcia-Conde, C Solano (31 (31) 12/19)
 Valencia, Hospital Infantil La Fe (peds, onco), CIC 653, V Castel, A Verdeguez, JM Fernandez (22 (23) 5/17)
 Valencia, Hospital Universitario La Fe (hem), CIC 663, MA Sanz, GF Sanz (72 (89) 39/33)
 Valencia, Hospital Doctor Peset (hem), P Ribas Garcia (8 (9) 0/8)
 Valencia, Instituto Valenciano de Oncologia, I Picón (7 (8) 0/7)
 Valladolid, Hospital Rio Hortega, CIC 611, J Garcia Frade (14 (16) 0/14)
 Vigo, Hospital Xeral-Cies, A Martínez-Dalmau (31 (33) 4/27)
 Zaragoza, Clinico Universitario Lozano Blesa (hem, onco), CIC 531, M Gutierrez, J Moreno, L Palomera (11 (12) 0/11)
 Zaragoza, Clinico Universitario Lozano Blesa (onco), A Tres, J Mayordomo (6 (6) 0/6)
 Zaragoza, Hospital Miguel Servet (hem + onco) M Giral, G Pérez-Lugmus, D Rubio-Félix, A Anton (23 (24) 5/18)

Sweden (9 team: 512 (599) 170/342)

Goteborg, CHECT (ads + peds), CIC 289, M Brune, A Fasth (96 (129) 28/68)
 Linköping, University Hospital (hem), CIC 740, N Theorin (44 (53) 13/31)
 Lund, University Hospital (hem), CIC 283, AN Bekassy, S Lenhoff (77 (88) 23/54)
 Malmö, University Hospital, T Ahlgren (9 (12) 0/9)
 Örebro, University Hospital (hem, onco), CIC 738, U Tidefelt (16 (19) 0/16)
 Stockholm (Huddinge), Karolinska University Hospital (hem, onco), CIC 212, P Ljungman (100 (111) 69/31)
 Stockholm, Karolinska Hospital (hem), CIC 626, M Björkholm (43 (43) 0/43)
 Umea, Norrland University Hospital, CIC 731, A Wahlin, V Lazarevic, J Lindh, B Markevärn (45 (55) 12/33)
 Uppsala, University Hospital (ads + peds), CIC 266, I Hassan, G Oberg (82 (89) 25/57)

Switzerland (9 teams: 331 (431) 92/239)

Aarau, Kantonsspital (hem, onco), CIC 316, M Wernli, M Bargetzi (25 (32) 0/25)
 Basel, Kantonsspital (hem, onco), CIC 202, A Gratwohl, T Kühne, R Herrmann (61 (89) 35/26)
 Bellinzona, Ospedale San Giovanni (hem, onco), CIC 829, F Cavalli, M Ghielmini, L Leoncini (16 (18) 0/16)

- Bern, Inselspital (ads, peds, hem, onco), CIC 221, K Leibundgut, C Zwicky, M Fey (43 (59) 0/43)
- Geneva, Hôpital Cantonal Universitaire (hem, onco), CIC 261, B Chapuis, Y Chalandon, P Wacker (24 (30) 24/0)
- Lausanne, CHUV (hem, onco), CIC 820, M Schapira, S Leyvraz, N Ketterer (58 (79) 0/58)
- St Gallen (hem, onco), Kantonsspital, CIC 324, U Hess (21 (23) 0/21)
- Zurich, University Hospital (ads, hem, onco), CIC 208, U Schanz, J Halter, Ch Taverna (63 (80) 18/45)
- Zurich, University Hospital (peds, hem, onco), CIC 334, R Seger (20 (21) 15/5)
- Tunisia** (1 team: 86 (94) 25/61)
- Tunis, Centre National de Greffe de Moelle Osseuse, CIC 183, B Othman (86 (94) 25/61)
- Turkey** (24 teams: 517 (543) 223/294)
- Adana Yuregir, Baskent University Adana Research and Training (hem), CIC 589, H Ozdogu (2 (2) 0/2)
- Adana, Cukurova University Hospital (ads, onco), CIC 821, B Sahin (20 (21) 0/20)
- Ankara-Sihhiye, Hacettepe University (hem), CIC 168, H Goker, O Ozcebe, I Haznedaroglu, S Dundar (12 (14) 9/3)
- Ankara-Besevler, Gazi University (hem), CIC 169, R Haznedar (20 (20) 10/10)
- Ankara, Hacettepe University, Institute of Oncology, CIC 292, E Kansu, Y Koc, E Ozdemir (44 (48) 14/30)
- Ankara-Etlik, GATA BMT Center, CIC 372, F Arpacı, A Özet, C Beyan, A Ural (49 (52) 13/36)
- Ankara, Ihsan Dogramaci Childrens Hospital, CIC 399, A Tuncer, D Uckan (22 (22) 22/0)
- Ankara, University School of Medicine Ibnı Sina Hospital (hem), CIC 617, G Gürman (52 (56) 29/23)
- Ankara, University of Ankara (peds), CIC 620, E Unal (13 (13) 9/4)
- Ankara, Numune Education and Research Hospital, CIC 691, M Ayli (52 (52) 32/20)
- Antalya, Akdeniz University Hospital (peds), CIC 618, MA Yesilipek, V Hazar, O Yegin (15 (17) 14/1)
- Antalya, Akdeniz University Hospital (hem), CIC 685, L Undar (21 (32) 8/13)
- Aydin, Adnan Menderes University Medical Faculty (hem), CIC 187, Z Bolaman (6 (6) 0/6)
- Bornova-Izmir, Ege University Medical Faculty (peds), CIC 621, S Kansoy (8 (8) 5/3)
- Bornova-Izmir, Ege University Medical Faculty (ads, hem), CIC 628, S Cagırgan (45 (51) 5/40)
- Eskisehir, Osmangazi University, CIC 686, Z Güblas (17 (17) 7/10)
- Istanbul, Marmara University (hem), Altunizade, CIC 714, T Akoglu (10 (10) 1/9)
- Istanbul, University of Istanbul, CIC 760, S Kalayoglu-Besısık (23 (23) 12/11)
- Istanbul, Cerrahpasa Medical School, CIC 761, B Ferhanoglu, T Soysal, Z Baslar (27 (27) 10/17)
- Istanbul, Tip Fakultesi (peds, hem, onco), CIC 762, G Gedikoglu (0 (0) 0/0)
- Istanbul, GATA Haydarpara Egitim Hast (hem, onco), CIC 687, A Öztürk (2 (2) 0/2)
- Izmir, Dokuz Eylul University (onco), CIC 688, U Yilmaz (14 (16) 3/11)
- Kayseri, Erciyes University Hospital (hem, onco), CIC 627, A Unal, M Cetin (33 (33) 15/18)
- Trabzon, Karadeniz Technical University (hem), CIC 170, E Ovalı (10 (10) 5/5)
- Ukraine** (2 teams: 24 (32) 1/23)
- Kiev, Kiev City BMT Center, CIC 176, E Karamanesht, V Khomenko, I Korenkova, S Borodkin (24 (32) 1/23)
- Kiev, Kiev Regional Oncologic Hospital (peds, hem, onco), CIC 177, S Donska, O Ryzhak (no report)
- United Kingdom** (51 teams: 2226 (2439) 794/1432)
- Aberdeen, The Royal Infirmary (hem), CIC 344, DJ Culligan (20 (20) 1/19)
- Bangor, Gwynedd Hospital (hem, onco), CIC 736, J Seale (15 (16) 0/15)
- Bath, Royal United Hospital (hem), CIC 619, C Knechtli (10 (10) 0/10)
- Belfast, Belfast City Hospital (hem), CIC 268, F Jones, TCM Morris, P Abram (37 (38) 5/32)
- Birmingham, Heartlands Hospital (hem), CIC 284, DW Milligan (44 (54) 11/33)
- Birmingham, Queen Elizabeth Hospital (hem), CIC 387, C Craddock, P Mahendra (121 (129) 38/83)
- Birmingham, The Birmingham Childrens Hospital (hem), CIC 781, PJ Darbyshire (37 (49) 21/16)
- Bournemouth, Royal Bournemouth Hospital (hem), Poole Hospital, Dorset Cancer Centre and Salisbury District Hospital, CIC 765, S Killick, J Cullis (19 (20) 0/19)
- Bristol, Royal Hospital for Children (allo, ads, peds), CIC 386:1, JM Cornish, D Marks (74 (84) 69/5)
- Bristol, Avon Haematology Unit (auto), CIC 386:2, R Evelyn, J Bird (22 (25) 0/22)
- Cambridge, Addenbrooke's Hospital (hem), CIC 566, C Crawley, RE Marcus, J Craig, H Balsdon, T Chapman (65 (75) 15/50)
- Cardiff, University Hospital of Wales (hem), CIC 303, KMO Wilson, AK Burnett, JA Whittaker, CH Poynton (58 (60) 14/44)
- Cheltenham, Cheltenham General Hospital, E Blundell (18 (19) 0/18)
- Coventry, University Hospital & Warwickshire NHS Trust, J Mills (16 (16) 0/16)
- Dundee, Ninewells Hospital (hem), CIC 719, D Meiklejohn (11 (11) 0/11)
- Edinburgh, Western General Hospital, (hem) CIC 228, JM Davies, PRE Johnson, MJ Mackie, PH Roddie, P Shepherd (35 (36) 6/29)
- Exeter, Royal Devon and Exeter Hospital (hem), CIC 571, C Rudin (14 (15) 1/13)
- Glasgow, Royal Infirmary, CIC 244, IG McQuaker, A Parker (66 (66) 34/32)
- Glasgow, The Western Infirmary (hem), CIC 325, T Fitzsimons (18 (18) 0/18)
- Glasgow, Royal Hospital for Sick Children (hem), CIC 707, B Gibson (15 (15) 11/4)
- Leeds, St James's University Hospital, The General Infirmary, Pinderfields Hospital CIC 254, G Cook, S Kinsey, MC Galvin (124 (135) 27/97)
- Leicester, Royal Infirmary (hem), CIC 713, AE Hunter (42 (48) 14/28)
- Liverpool, Royal Liverpool University Hospital (hem), CIC 501, RE Clark, A Pettitt (54 (56) 15/39)
- Liverpool, Alder Hay, CIC 773, M Caswell (11 (11) 6/5)
- London, Hammersmith Hospitals NHS Trust, CIC 205, J Apperley, E Olavarria, E Kanfer, A Rahemtulla, R Szydlo (114 (126) 50/64)
- London, Royal Free Hospital (hem), CIC 216, S Mackinnon (51 (59) 35/16)
- London, Royal Marsden Hospital (hem), CIC 218, M Potter (100 (120) 31/69)
- London, University College Hospital (onco), CIC 224, J Whelan (10 (10) 0/10)
- London, University College Hospital (hem), CIC 224, K Thomson (136 (136) 36/100)
- London, Great Ormond Street Hospital, CIC 243, P Veys (58 (63) 52/6)
- London, The London Clinic (hem), CIC 263, P, Gravett, M Potter (14 (18) 4/10)
- London, St George's Hospital (hem), CIC 539, J Marsh, S Ball, EC Gordon-Smith (21 (22) 14/7)
- London, Guy's Hospital (hem), CIC 721, M Kazmi (22 (25) 3/19)
- London, King's College (hem), CIC 763, GJ Mufti, A Pagliuca (96 (103) 64/32)
- London, St Bartholomew's, CIC 768 and the Royal London Hospital, J Cavenagh, S Agrawal, T Lister (70 (74) 14/56)
- Manchester, Royal Children's Hospital, CIC 521, R Wynn (26 (32) 22/4)
- Manchester, The Royal Infirmary, CIC 601, JA Yin (47 (50) 28/19)
- Manchester, Christie Hospital (hem), CIC 780, E Liakopoulou (46 (58) 11/35)
- Manchester, Trafford General Hospital, PA Carrington (2 (2) 0/2)
- Newcastle upon Tyne, Royal Victoria Infirmary and the Sunderland Royal Hospital, CIC 276, GH Jackson, SJ Proctor, P Taylor, A Cant, R Skinner PJ Carey (96 (106) 39/57)
- Norwich, Norfolk and Norwich Hospital (hem), CIC 391, J Parker, G Turner (12 (13) 0/12)
- Nottingham, City Hospital, CIC 717, N Russell, JL Byrne, AP Haynes, A McMillan (119 (137) 45/74)
- Oxford, John Radcliffe Hospital (hem, onco), Headington and Wycombe General, CIC 255, TJ Littlewood, C Bunch, C Mitchell, C Haton, G Hall, J Wainscoat (52 (57) 15/37)
- Plymouth, Derriford Hospital, CIC 823, MD Hamon (36 (37) 6/30)
- Salford, Hope Hospital, PA Carrington (9 (9) 0/9)

Sheffield, Royal Hallamshire Hospital – J Snowden, Weston Park Hospital – L Evans
 Rotherham General Hospital – H Barker and the Children’s Hospital – A Vora, CIC 778:1/2/3/5 (60 (68) 22/38)
 Somerset, Taunton and Somerset Hospital S Bolam, SA Johnson (7 (7) 0/7)
 Southampton, CRC Wessex, CIC 704, K Orchard, A Duncombe, J Kohler (58 (63) 15/43)
 Stoke-on-Trent, University Hospital of North Staffordshire (hem), CIC 394, R Chasty (5 (5) 0/5)
 Swansea, Singleton Hospital, Skett, S Al Ismail (7 (7) 0/7)
 Swindon, Great Western Hospital (Hem), CIC 608, NE Blesing, A Gray, S Green, A Koster (6 (6) 0/6)

Yugoslavia (Serbia and Montenegro) (4 teams: 29 (30) 12/17)
 Belgrade, Mother and Child Health Institute, CIC 358, D Vujic (8 (8) 2/6)
 Belgrade, Clinical Centre of Serbia (hem), CIC 373, M Colovic, A Bogdanovic (0 (0) 0/0)
 Belgrade, Military Medical Academy (hem), CIC 582, L Ristic 20 (21) 9/11
 Novi Sad, Institute of Internal Diseases, Clinical Centre of Novi Sad (hem), CIC 655, S Popovici (1 (1) 1/0)

Total Europe 2004: 22216 (26594) 7407/14809

*Late report included in Appendix only.
 February 2006